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ABSTRACT OF THE DISSERTATION
STRUCTURAL BASIS FOR CHLOROPEROXIDASE CATALYZED
ENANTIOSELECTIVE EPOXIDATIONS AND MECHANISMS OF
SELECTED ANTICANCER DRUG INDUCED APOPTOSIS
by
Yongjian Guo
Florida International University, 2019
Miami, Florida
Professor Xiaotang Wang, Major Professor
Chloroperoxidase (CPO), a member of the heme peroxidase family, has
diverse catalytic activities toward a broad range of substrates. CPO also catalyzes
reactions typical of traditional heme peroxidases, catalases, and cytochrome
P450 enzymes. To overcome these shorting comings of the protein, we
investigate the fabrication and characterization of chloroperoxidase (CPO) and
glucose oxidase (GOx) on the surface of MGO. Chapter 2 of this dissertation
demonstrates the feasibility of co-immobilizing CPO and GOx onto MGO and
the potential of MGO-GOx-CPO in environmental applications. The heme active
site structure has also been thought to be responsible for the enantioselectivity of
CPO. Chapter 3 of this dissertation investigates the structural factors that
contribute to CPO’s stereoselectivity in catalyzing epoxidation reactions. The
characterization of CPO-substrate complex will be carried out using UV-Vis
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spectrophotometry and nuclear magnetic resonance (NMR) spectroscopy. We
will focus on understanding the mechanism of CPO-catalyzed enantioselective
epoxidation and structure-activity relationship of CPO.
Non-small-cell lung carcinoma (NSCLC) continues to be a vital human
healthcare problem worldwide for its high incidence and consequent mortality
rate. We investigated the anticancer effect of LZ-101, a novel derivative of
danofloxacin, against non-small-cell lung cancer and the underlying mechanisms.
We demonstrated that LZ-101 induced mitochondrial-mediated apoptosis by
increasing Bax/Bcl-2 ratio, loss of mitochondrial membrane potential (ΔΨm),
cytochrome c (Cyt c) release and apoptosis-inducing factor (AIF) transposition
in A549 cells. Moreover, we found that LZ-101 increased the stability of
FOXO3a by blocking autophagy-dependent FOXO3a degradation.
Enhanced energy metabolism plays important roles in the growth and survival
of cancer cells. Here, we investigated the mechanisms of a newly synthesized
flavonoid, GL-V9, in the inhibition of glycolysis and the induction of apoptosis
of human breast cancer cell lines MDA-MB-231 and MCF-7 cells. GL-V9 not
only downregulate the expression of HKII in MDA-MB-231 and MCF-7 cells,
but also induce dissociation of HKII from voltage-dependent anion channel
(VDAC) in mitochondria, resulting in glycolytic inhibition and mitochondrialmediated apoptosis. Our work demonstrates the significance of metabolic
regulator in cancer growth and offers fresh insight into the molecular basis for

vii

the development of flavonoid as novel agents for the treatment of breast
carcinoma.
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CHAPTER I.
INTRODUCTION
1.1 Proteins and Peroxidases Containing Heme Prosthetic Group
Heme-thiolate proteins are a group of hemoproteins whose prosthetic group is
protoheme (Figure 1) with a thiolate anion of a cysteine residue as the axial ligand.
They constitute one of the two major hemoprotein groups found in living organisms;
the other is the ‘‘heme–imidazole protein’’ group that includes hemoglobin [1].

Figure 1.1 Structure of Heme-thiolate proteins (Iron protoporphyrin IX).

Cytochrome P450 was the first hemoprotein found to have a 450-nm absorption peak
in the carbon monoxide-binding spectrum. However, we now know that cytochrome

1

P450 is a member of the growing family of heme-thiolate proteins, in which nitric oxide
synthase is another important member. The major physiological function of hemethiolate proteins is apparently the activation of molecular oxygen for a various of
oxygenase reactions [2]. Chloroperoxidase (CPO), a member of the heme peroxidase
family, has diverse catalytic activities toward a broad range of substrates. Peroxidase is
a striking group of enzymes that can catalyzes the oxidation of many substrates using
peroxide as a co-substrate. These enzymes have been discovered and used for decades.
Among the peroxidases, CPO has attracted more attention for deciphering the
mechanism of its unique reactions and for using this enzyme to serve humanity life. In
addition to catalyzing halogenation reactions involved in the biosynthesis of halogencontaining compounds, CPO also catalyzes reactions typical of traditional heme
peroxidases, catalases, and cytochrome P450 enzymes [3]. The versatility of CPO has
long been attributed to the unique structural components of the protein environment
that constitute the heme active site, particularly the identity of the axial heme ligand
and amino acid residues distal to the heme iron. The heme active site structure has also
been thought to be responsible for the enantioselectivity of CPO.
1.2 NMR of Paramagnetic Systems
The completion of the human genome, together with that of an increasing number
of other living systems including pathogens, poses problems in structural biology
preceding the challenge of high throughput generation of 3D structures of gene products,
namely proteins. The biological NMR community, in particular, needs to overcome
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several intrinsic limitations of the technique including the presence of paramagnetic
metals in the molecule, which may be a source of severe line broadening [4].

Figure 1.2 The inner sphere centered on the paramagnetic metal ion is a blind-zone, as proton
NMR signals are too broad to be detected. Outside this sphere, there is another sphere
indicating the region where NMR signals are visible and still affected by paramagnetism, so
that information can be extracted on their position with respect to the metal ion [4].

While it has long been recognized that both the hyperfine shifts and paramagnetic
relaxation can provide unique and valuable information on the electronic, magnetic,
and molecular structural properties of the active site of paramagnetic metalloproteins,
access to this information has been thwarted by the absence of a systematic and reliable
strategy for assigning the resonances to specific nuclei in the molecule. Thus, the initial
excitement about and interest in NMR spectroscopy of paramagnetic proteins in the late
60s to middle 70s of the last centuries faded somewhat on the full realization of the
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apparent barriers to unambiguous signal assignment. The early strategies for assigning
hyperfine-shifted resonances in a paramagnetic protein relied on a number of methods,
of which most had only a very limited applicability.
As the estimated fraction of metalloproteins is about one third of the total proteins,
and a significant number of these are paramagnetic, the issue is not an irrelevant one.
The increasing number of NMR groups that have begun tackling paramagnetic systems
in the last few decades. It has been increasingly recognized that, besides contributing
to line broadening, the electron nucleus interactions contain useful structural
information. The first protein solution structure was published in 1985 and since then
NMR spectroscopy has developed through diamagnetic molecule applications. The
broadening due to Para magnetism seemed an insurmountable obstacle for structure
determination. However, some groups continued to deepen the understanding of the
effects of hyperfine coupling in NMR spectroscopy and simultaneously to exploit
technological advancements to increase the signal-to-noise ratio of paramagneticsystem spectra. Eventually, a protocol for solving the structure of a paramagnetic
metalloprotein was reported in 1994 and since then many examples have appeared in
the literature [5]. The paramagnetic property of the metalloprotein also serves as an
intrinsic probe for elucidating the structural properties of enzyme-substrate complexes
as will be exploited in Chapter 3 of this dissertation.
1.3 NMR Application to Heme-Peroxidases
Every metal ion has its own peculiarities and should be regarded as special cases.
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For example, Low-spin iron (iii): its sphere of non-observability for proton NMR
spectroscopy is quite narrow and its compounds represent the most popular class of
paramagnetic compounds studied by NMR spectroscopy. Many of the relevant effects
that the presence of paramagnetic metals has on the behavior of the protein nuclei have
to do with the metal magnetic susceptibility. Previous literature has reported that the
presently available homonuclear NMR methods allow productive investigation of the
active site of ∼40 kDa high-spin ferric heme enzymes, albeit with a more limited
information content relative to similar studies on the low-spin, cyanide-inhibited
derivatives [6]. Identification of peripheral aromatic contacts allows the determination
of the zero-field splitting constant by their characteristic temperature dependence if a
homology model is available. It is expected that changes in shifts in resting state
peroxidases upon systematic perturbation, such as substrate binding (or point mutation),
should be accessible to interpretation in terms of the electronic structure of the heme
iron [6].
1.4 CPO Catalyzed Reactions
The crystal structure of CPO reveals the unique structural feature of this versatile
biocatalyst [2]. CPO contains a single polypeptide chain of 299 amino acids that folds
into 8 helixes, named A~H, as shown in Figure 3 [7].
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Figure 1.3 The crystal structure of Chloroperoxidase showing the two channels (narrow, green,
wide, blue) that connect the heme active site to the surface.

Chloroperoxidase(CPO) is unusually versatile, capable of catalyzing not only the
reactions typical of peroxidases but also those of catalases and monooxygenases, as
well as halogenation reactions. The structure of CPO shares many common features
with that of cytochrome P450 with a merged region containing the proximal ligand and
ligand binding site distal to the heme. However, the structure of CPO also displays
essential differences from other heme peroxidases and cytochrome P450. Thus, the
catalytic activity of CPO is more auspicious especially in making chiral synthons such
as epoxides. Chiral epoxides are very important intermediates for the synthesis of
optically pure complex molecules, particularly biologically active compounds [8].
Catalytic asymmetric epoxidation of alkenes is one of the most powerful strategies for
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the preparation of enantiomerically pure epoxides. A better understanding of the
mechanisms of CPO catalyzed enantioselective oxidations would provide guidance to
design mutant proteins that display improved catalytic activity and enantioselectivity.
1.5 The Mechanism of CPO Catalyzed Reactions
Chloroperoxidase can catalyze various reactions including halogenation,
monooxygenation,

dismutation,

and

peroxidation. An

important

aspect

of

chloroperoxidase catalysis is the mode of binding of the substrate to the active site [9].
Compound I is an oxidized ferryl heme with a porphyrin radical intermediate, which
was found in the catalytic cycle of many peroxidases and P450s. The reactive species
could be generated by reacting the resting or ferric state of CPO with a peroxide
molecule. Compound I can go through different pathways in the catalytic cycle [10].
For example, during halogenation reactions, compound I is a strong oxidant and can
react with chloride ions to produce HOCl (Fig 1.4).
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Figure 1.4 The catalytic cycle of chloroperoxidase (CPO). X represents Cl, Br or I involved in
the halogenation pathway [11]

During this process, Compound II, an oxo-ferryl heme, will form after one electron
reduction of Compound I [12]. After another one-electron reduction Compound II is
returned to ferric state.[11]. The lack of stereospecificity in the halogenation reactions
catalyzed by CPO is in agreement with the participation of an “enzyme-free”
halogenating species, the details remains to be a matter of debate.
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1.6 Applications of CPO
1.6.1 Enhancing the Applicability of CPO
Enzyme catalysis has drawn an increasing amount of attention in both academia and
industry because of its large potential in the manufacture of value-added fine chemicals,
pharmaceuticals, flavors, and fragrances under mild conditions with high yield and
selectivity [13]. Chloroperoxidase has long been recognized as a versatile catalyst for
its powerful and diverse catalytic activities [14, 15]. However, like most biological
catalysts, practical applications of CPO are often hampered by the difficulty in
regenerating the active enzyme and the lack of long-term operational stability of the
protein, especially in the presence of high concentrations of peroxide and at elevated
temperatures [16].
To overcome these drawbacks, tremendous efforts have been made to immobilize
enzymes on appropriate supporting materials [17]. However, enzyme bound on a
support often display lower activity than that of the free enzyme because of enzyme
deactivation during immobilization and/or increased transfer resistance of substrate in
the support. Graphene oxide/iron oxide (MGO) composites have been regarded as one
of the most promising supporting materials for the immobilization of enzymes. The
magnetism of the composites allows easy separation of the enzyme for reuse while the
unique surface property of the composites significantly enhances the catalytic
performance of the enzyme. The improved enzyme performance can be attributed to
such factors as enhanced enzyme purity [18], stability (including the possibility of
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enzyme reactivation, especially for multimeric enzymes, such as glucose oxidase),
activity, selectivity, decreased inhibition and mass transport limitations [19, 20].
Cascade reactions taking place in one pot offer the second enzyme the opportunity
to act on a higher concentration of its substrate. Meanwhile, cascade reactions
significantly reduce the length of time required for the full reaction course. However,
cascade reactions have at least these two shortcomings. First, since both enzymes are
immobilized on the same surface, the loading amount of enzyme becomes restricted.
Second, when one enzyme is inactivated, the other will have to be discarded even if it
is still fully active [21].
So far various support and composite materials, such as synthetic resins,
biopolymers, and inorganic solids (mesoporous silicas or zeolites) have been developed.
The properties of the support materials define their interaction with the enzyme and are
thus critical to enzyme activity after immobilization. Therefore, nanostructure
composite and hybrid materials have gained increasing attention because of their
potential to improve the efficiency of enzyme immobilization [22] as exemplified in
Chapter 2 of the dissertation.
1.6.2 Environmental Applications
A number of oxidative enzymes from bacteria, fungi and plants have been reported
to play an important role in numerous waste treatment applications. Peroxidases and/or
phenoloxidases act on specific recalcitrant pollutants by precipitation or transformation
of the pollutants to other products and permitting a better final treatment of the
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waste[23]. Improvement in the useful life and thereby a reduction in treatment cost has
been accomplished through enzyme immobilization.
Horseradish peroxidase, lignin peroxidase and manganese peroxidase mineralize a
variety of recalcitrant aromatic compounds. Immobilization of these enzymes on
porous ceramic supports or resins did not adversely affect their stability and showed a
good potential for degradation of environment persistent aromatics.
According to a recently published work, CPO has been reported to oxidize several
phenolic compounds [23] . In addition, oxidation of ethanol to aldehyde and oxidation
of chloride ions occurred [24]. Recently, the application of free form of CPO was
reported in many kinds of oxidation processes [25]. The enzyme was purified and
immobilized on an aminopropyl glass, on talc or on reverse micelles [1, 25]. A combined
electrocatalytic approach using immobilized CPO and a glucose electrode has been
developed for the measurement of chlorophenol congeners.
There is a growing recognition that enzymes can be used in many remediation
processes to target specific pollutants for treatment. Recent biotechnological advances
have allowed the production of cheaper and more readily available enzymes through
better isolation and purification procedures [26-28]. The potential advantages of the
enzymatic treatment as compared with conventional treatments include: application to
recalcitrant materials, operation at high and low contaminant concentrations over a
wide pH, high temperature and salinity range, needs of biomass acclimatization and the
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easy control process among others. The most recent research in this area have focused
on the development of enzyme processes for the treatment of wastewater [26].

1.6.3 Pharmaceutical Applications
Chloroperoxidase is able to catalyze a broad spectrum of stereoselective
hydroxylation, sulfoxidation and epoxidation reactions. The substrate specificity of
chloroperoxidase for chiral epoxidation of mono- and disubstituted alkenes has been
well documented as summarized in Figure 1.5. Chloroperoxidase is able to efficiently
utilize alkenes with chain lengths of nine or fewer carbon atoms except for
monosubstituted terminal olefins which often function as reversible suicide inhibitors
of the enzyme. Excellent substrates are created by cis-1 methyl and 2-methyl
substitutions on the olefinic double bond. Kinetic, enantioselectivity and epoxide yield
data have been obtained on a series of brominated and unbrominated methallyl alkenes
and substituted styrenes. The results indicate that methallyl alkenes and styrenes can
function as good substrates [29].
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Figure 1.5 The asymmetric epoxidation reactions catalyzed by chloroperoxidase [7].

Many of the epoxide products derived from chloroperoxidase catalysis can serve as
chiral synthons for drug and natural product synthesis. Chloroperoxidase is a readily
available and considerably stable enzyme that is well suited for important and valuable
synthetic strategies. However, the structural basis for Chloroperoxidase catalyzed chiral
reactions has not been well understood. One of the main tasks of my projects is to
elucidate the mechanisms of such reactions as will be discussed in Chapter 2 of this
dissertation.
1.7 Anticancer Effects of Selected Natural Product Derivatives
Wogonin is a plant flavonoid extracted from Scutellaria baicalensis (Figure 1.6 )
and has been studied by many researchers for its anti-viral, anti-oxidant, anti-cancerous
and neuro-protective properties [30]. During the last 20 years, wogonin (WG; 5,7dihydroxy-8-methoxyflavone) was identified as a potent apoptosis inducer of cancer
cells with good efficacy and minor side effects. Furthermore, pharmacokinetic studies
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in rats support the possible use of WG in clinic applications. It has been approved for
Phase I clinical trials in China.

Figure 1.6 Scutellaria baicalensis Georgi (Huang Qin) and WG. (A) The plant of Huang Qin.
(B) The chemical structure of WG. Abbreviation: WG, wogonin [31].

Several studies have shown its inhibitory activity on the viability and the growth of
tumor cells. Various investigations have also demonstrated that WG exerts its antitumor
effects via regulation of multiple molecular pathways. The key molecular pathways of
its antitumor effects include reactive oxygen species (ROS), Ca2+, NF-κB, tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL), and tumor necrosis factoralpha, which participates in both intrinsic mitochondria-mediated and extrinsic
receptor-mediated pathways. In addition to its activation of Bax/Bak protein and
caspase-8/caspase-9/caspase-3,

WG

plays

an

important

role

in

inhibiting

lipopolysaccharide-induced or hydrogen peroxide (H2O2)-induced tumor angiogenesis
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through PI3K/AKT/NF-κB signaling pathway. In addition, the ability of WG to inhibit
tumor angiogenesis by decreasing the expression of hypoxia-inducible factor-1α (HIF1α) protein was also observed. All those ablity is aiming to summarize its new
developments for its future clinical use.[31]. The results of my studies on two
derivatives of WG demonstrated the potential of improving the biological activity of
this natural product and offers new insights into the mechanisms of the anticancer
activity of this class of compounds.
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CHAPTER II.
ENHANCING THE CATALYTIC PERFORMANCE OF
CHLOROPEROXIDASE BY CO-IMMOBILIZATION WITH GLUCOSE
OXIDASE ON MAGNETIC GRAPHENE OXIDE
2.1 Background
Although chloroperoxidase (CPO) has long been recognized as a powerful and
versatile catalyst, its applications have been thwarted by the difficulty in regenerating
the active enzyme and substrate (peroxide) induced protein inactivation. In this paper,
we describe the fabrication and characterization of CPO and Glucose Oxidase (GOx)
on the surface of Magnetic Graphene Oxide (MGO). The performance of the
immobilized CPO was considerably enhanced by coupling with GOx that provided the
required H2O2 in situ through glucose oxidation. The activity of MGO-GOx-CPO
(96.6%) towards the decolorization of orange G was much superior to that of MGOGOx + MGO-CPO (86.2%), probably as a result of reduced mass transfer resistance
between CPO and H2O2 generated from GOx molecules. Interestingly, MGO-GOxCPO reached its peak activity (95.2%) when temperature was maintained between
42 °C and 50 °C compared to the optimal temperature of 35 °C for the free enzyme,
possibly due to dispersion of the otherwise stacked MGO below 42 °C. Finally, MGOGOx-CPO can be conveniently reused for its ease of recovery in the presence of an
external magnetic field, with ∼38.5% activity remained after 6 cycles of applications.
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This work demonstrates the feasibility of co-immobilizing CPO and GOx onto MGO
and the potential of MGO-GOx-CPO in environmental applications.
2.2 Experimental Procedure
2.2.1 Materials & Methods
2.2.1.1 Materials
Chloroperoxidase was isolated from the growth medium of Caldiamides fumago
according to the method of Morris and Hager [9] with minor modifications as described
previously [32]. The activity of CPO used in this study was 4800 U/mL based on the
standard monochlorodimedon (MCD) assay [33]. The stock CPO was kept in 0.1 mol/L
phosphate buffer (pH 5.0) at 4 °C Glucose oxidase was purchased from Sigma-Aldrich
(10 kU/29 mg). β-D-glucose was obtained from Tokyo Chemical Industry Co. Ltd.
Graphite, (NH4)2Fe(SO4)2·6H2O, NH4Fe(SO4)2·12H2O, NH3·H2O, KH2PO4, K2HPO4
and H2SO4 (98%) were acquired from Sinopharm Chemical Reagent Co. Ltd. H2O2 (30%
in aqueous solution), NaNO3 and KMnO4 were provided by Xi'an Chemical Reagent
Factory. All chemicals were of analytical grade and used without further purification.
2.2.1.2 Preparation of MGO
GO was prepared from graphite powder according to published method [34, 35].
Briefly, 1.0 g of graphite powder and 0.5 g of NaNO3 in 75 mL of concentrated H2SO4
were stirred in an ice-water bath, 3.0 g of KMnO4 was then added gradually with
constant stirring. After the stirring was continued for 2 h at temperatures below 10 °C,
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the ice bath was removed, and the mixture was stirred at 35 °C for another 30 min. The
reaction mixture was diluted with 45 mL of distilled water and the temperature was
increased to and kept at 98 °C for 30 min. The reaction was terminated by adding 140
mL of distilled water, followed by the addition of 6 mL of 30% H2O2. The resulting
reaction mixture was centrifuged and washed several times with 5% HCl solution, then
by deionized water until the pH of the supernatant became neutral. The GO obtained
was dried for the preparation of the magnetic Fe3O4/GO composites.
The MGO composites were prepared by co-precipitating (NH4)2Fe (SO4)2·6H2O and
NH4Fe(SO4)2·12H2O in the presence of GO. Briefly, 5.8 g of (NH4)2Fe(SO4)2·6H2O
and 10.7 g of NH4Fe(SO4)2·12H2O were dissolved in 100 mL of deionized water under
an argon atmosphere and stirred for 30 min. GO (1.0 g) in 100 mL of water was
ultrasonicated for 1 h and was then added slowly to the (NH4)2Fe(SO4)2·6H2O and 10.7
g of NH4Fe(SO4)2·12H2O mixture along with ammonia with constant stirring for 45
min at 85 °C. When the solution was cooled to room temperature, the black precipitates
(MGO composites) were washed with deionized water and dried in a vacuum.
2.2.1.3 Immobilization of CPO and GOx
Immobilization of enzyme molecules was achieved by physical ad- sorption of the
enzymes onto the surface of MGO sheets. Briefly, 0.25 mg MGO in 1.5 mL phosphate
buffer was ultrasonicated for 30 min and then separated by magnetic decantation.
Subsequently, the MGO was mixed with 10 μL (0.15 mmol/L) CPO in 1.5 mL
phosphate buffer and incubated with constant shaking at 20 °C for 25 min. CPO
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absorbed on MGO (MGO-CPO) was magnetically separated from free CPO and rinsed
twice with phosphate buffer. The MGO-GOx was obtained using the same procedure
with GOx replacing CPO in the preparation of MGO-CPO.
The MGO-GOx-CPO was also obtained with the same procedure by replacing the
individual enzyme solution with a mixture of 10 μL (0.15 mmol/L) CPO and 5 μL (29
mg/mL) GOx.
2.2.1.4 Characterization of the carrier and the immobilized enzyme
X-ray Powder diffraction (XRPD) was performed on a D/MAX-2550/PC
diffractometer at 40 kV and 30 Ma using Cu Kα radiation (λ = 0.15406 nm).
Transmission electron microscopy (TEM) images were obtained with a JEM-2100
microscope at an accelerating voltage of 200 kV. Scanning electron microscopy (SEM)
images were recorded on a FEI Quanta 200 microscope at an accelerating voltage of 20
kV. Laser scanning confocal microscopy images were taken on an Olympus FV1200
confocal microscope with the detection wavelengths at 488 nm and 559 nm for
fluorescein isothiocyanate (FITC) and rhodamine B isothiocyanate (RhB) respectively,
where 8 mg of fluorescein iso- thiocyanate (FITC) or rhodamine B isothiocyanate (RhB)
dissolved in DMSO (2 mg/mL) was slowly added in to 1 mL of GOx or CPO solution
(in pH 9). The solution was shaken for 8 h at 200 rpm in dark. Then, free FITC or RhB
was removed by dialysis and the fluorescent molecule-labeled enzymes were obtained.
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2.2.1.5 Enzyme activity
The catalytic activity of the free and immobilized CPO was determined based on
their efficiency to decolorize Orange G [36, 37]. The reaction was carried out in 1.5 mL
mixtures containing 0.125 mmol/L Orange G, free or immobilized CPO (2.0 × 10-10
mol) in phosphate buffer (pH 3.0) and appropriate concentrations of H2O2 (for free CPO
and MGO-CPO) or β-D-glucose (for MGO-GOx + MGO-CPO and MGO-GOx-CPO).
The decolorization efficiency was measured within 30 min for free CPO or MGO-CPO,
and 60 min for MGO-GOx + MGO-CPO or MGO-GOx-CPO. All experiments were
repeated at least three times under the same conditions. Control was performed without
enzyme while keeping other conditions identical. The percent degradation was
measured by following the absorbance change at 478 nm using a Shimadzu UV-1700
UV–vis spectrophotometer and calculated using the following equation:
Decolorization efficiency (%) = [(A0 − At)/A0] × 100%
Where A0 is the initial absorbance and At stands for absorbance after “t” min of
reaction.
2.2.1.6 Effects of supporting material on the adsorption of dye
Appropriate amount of dye was added to 0.50 mg of the carrier or carrierimmobilized CPO. When the adsorption equilibrium is reached (∼20 min), the
adsorption rate was calculated by measuring the absorbance at 478 nm. H2O2 or β-Dglucose was added to the solution for decolorization of the dye. Then the buffer was
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added to the carrier with adsorbed dye after magnetic separation. The desorption of dye
was carried out in a thermostatic oscillator (200 r/min) at 30 °C for 3 h and the amount
of dye found in the supernatant was analyzed by measuring the absorbance at 478 nm.
At the same time, the carrier (without immobilized enzymes) with magnetic separation
was achieved after the adsorption reached equilibrium. The same experiment of dye
desorption was carried out and the absorbance value of the supernatant was measured.
2.2.1.7 Kinetic properties of the immobilized CPO
Kinetic assay for CPO-catalyzed degradation of Orange G was car- ried out over the
concentration range of 0.05∼0.125 mmol/L at optimal conditions (pH 3.0, 20 ℃, 30
min, 0.25 mmol/L of H2O2 (for free and MGO-CPO); pH 3.0, 20 ℃, 60 min, 23 mmol/L
of β-D-glucose (for MGO-GOx-CPO) established from our optimization experiments.
The kinetic parameters including Michaelis constant (Km), maximum rate of reaction
(Vmax), turnover number (kcat), and catalytic efficiency (kcat/Km) were calculated from
the Lineweaver-Burk plots.
2.2.1.8 Degradation of acid blue 45 and crystal violet with MGO-GOx-CPO
As a model reaction, the decolorization efficiency of Orange G was used to measure
the catalytic activity of MGO-GOx-CPO. To test if the MGO-GOx-CPO can also
degrade other dyes, acid blue 45 and crystal violet were used as substrates to evaluate
the catalytic efficiency of CPO co-immobilized with GOx. The assay was carried out
in 1.5 mL phosphate buffer (0.1 mol/L, pH 3.0) containing 2.0 × 10-10 mol CPO and
0.17 mM acid blue 45 or 0.045 mM crystal violet. The reaction was monitored for 30
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min at the characteristic absorbance of acid blue 45 or crystal violet at 595 and 584 nm,
respectively.
2.2.1.9 Degradation of Orange G in wastewater sample MGO-GOx-CPO
The potential application of MGO-GOx-CPO to remove dye from actual
environmental samples was evaluated by the degradation of Orange G in industrial
wastewater. The wastewater samples were collected from Hei river, Fengyu (naturally
running river water), Qinzhen (running urban water) and man-made lake (still water),
respectively. The degradation of orange G is carried out following the same procedure
with identical conditions as described in the previous sections, except that buffer was
replaced by wastewater sample at pH 3.0 adjusted with 1.0 mol/L HCl.
2.2.1.10 Thermal stability of CPO in different states
Free CPO, MGO-CPO, MGO-GOx + MGO-CPO, MGO-GOx-CPO in 0.1 mol/L
phosphate buffer (pH 5.0) was pre-incubated for 60 min at various temperatures (20,
30, 40, 50, 60 and 70 °C) in a closed thermostatic water bath. The thermal stability of
the enzyme was tested and expressed as residual activity (the ratio of activity before
and after incubation at different temperatures) or was determined as a function of
reaction time (0-24 h) at 50 °C.
2.2.1.11 Reusability of the MGO-enzymes
The reusability of MGO-CPO, MGO-GOx + MGO-CPO, and MGO- GOx-CPO was
determined and expressed as residual activity with the activity of the first run defined
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as 100%. The immobilized CPO was recovered after each reaction cycle by magnetic
decantation and washed with phosphate buffer (pH 5.0).
2.3 Results& Discussion
2.3.1 Characterization of supporting materials and immobilized enzymes
X-ray powder diffraction (XRPD) is one of the most powerful methods for the study
of crystalline and partially crystalline solid-state materials and has been widely used in
the study of graphene related materials [38, 39]. Figure 2.1 shows the XRPD data of
the graphite in comparison with GO (a) and MGO (b). The most striking feature is the
typical graphene (002) signature at 26.6°. The sharp and intense peak of the diffraction
pattern indicates high quality of the crystals [40].

Figure 2.1 XRPD patterns of (a) graphite compared with GO and (b) MGO.

Usually, as graphene is oxidized to graphene oxide, the signature peak of graphene
disappears and a new peak at a much smaller angle (around 10.4°) appears with an
index of (001) (Fig. 1a). These peaks were more intense in the case of Fig. 1b due to
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higher concentration of Fe3O4 nanoparticles in the sample. The XRPD peaks were
indexed to (220), (311), (511) and (440) planes of a cubic unit cell of magnetite,
appearing at 30.3°, 35.7°, 57.0° and 62.7°, respectively (JCPDS 65–3107). Figure 2.1
also revealed that except for the peaks assigned to Fe3O4, no diffraction peaks were
assignable to GO indicating that the stacking of GO sheets in the composites was
disordered [41].
The morphologies of GO, MGO and MGO-enzymes were characterized by
transmission electron microscopy (TEM) (Figure 2.2a–c) and scanning electron
microscopy (SEM) (Figure 2.2d–f). Both TEM and SEM suggested that GO had
crumpled sheet-like structures (Figure 2.2a and 2.2d) and Fe3O4 nanoparticles were
sparsely deposited and unevenly distributed on the surfaces of GO (Figure 2.2b and
2.2e). Figure 2.2c and 2.2f were the TEM and SEM images, respectively, of MGOenzymes. Although the GO sheet was clearly visible compared with MGO composites,
the number of particles on the carrier was increased, suggesting that the immobilized
enzyme was adsorbed on the carrier and did not significantly influence the morphology
of the composites.
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Figure 2.2 TEM images of GO (a), MGO (b), MGO-enzymes (c) and SEM images of GO (d),
MGO (e), MGO-enzymes (f).

To further confirm the immobilization of protein on MGO, GOx and CPO were
labeled with fluorescent probes fluorescein isothiocyanate (FITC) and rhodamine B
isothiocyanate (RhB), respectively. Confocal laser scanning microscopy (CLSM,
Figure 2.3) did show the simultaneous presence of both FITC–CPO (green) and RhB–
GOx (red) on the surface of MGO.

Figure 2.3 Laser scanning confocal microscope images of MGO (a), MGO-CPO (FITC) (b),
MGO-GOx (RhB) (c) and MGO-CPO (FITC) -GOx (RhB) (d).

The detection of protein (CPO/GOx) is carried out by HPLC equipped with a UV/Vis
detector set at 280 nm. The concentration of CPO and GOx in MGO-GOx-CPO is 1.4
× 10-7 mol/L and 9.3 × 10-8 mol/L, respectively, based on the of enzyme concentration
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before and after immobilization. The molar ratio of CPO:GOx in MGO-GOx-CPO is
3:2.
2.3.2 Effects of reaction parameters on the efficiency of orange G decolorization
The effects of reaction parameters including H2O2 and β-D-glucose concentration
were investigated on the decolorization of orange G by MGO-GOx + MGO-CPO or
MGO-GOx-CPO.
For MGO-CPO, the decolorization rate increased significantly at low H2O2
concentrations and reached a plateau when H2O2 concentration was increased to 0.25
mmol/L as shown in Figure 2.4a. When H2O2 concentration was further increased (up
to 1.0 mmol/L), the degradation rate decreased, possibly due to inactivation caused by
internal oxidative destruction of the enzyme’s heme active site [37]. Therefore, an
initial H2O2 concentration of 0.25 mmol/L was chosen for the rest of this study.

Figure 2.4 Effects of reaction parameters on the efficiency of Orange G decolorization: (a)
H2O2 concentration for MGO-CPO and free CPO; (b) β-D-glucose concentration for MGOGOx + MGO-CPO; (c) β-D-glucose concentration for MGO-GOx-CPO.

However, variations in glucose concentration between 0.1 and1.0 mol/L had little
effect on the rate of formation with no more than 0.30 μmol/min H2O2 in a 0.1 mol/L
glucose solution for a reaction time of 1600 min [42]. Therefore, the deactivation of
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CPO in this work can be avoided due to hydrogen peroxide generation in situ.
For MGO-GOx + MGO-CPO and MGO-GOx-CPO, the experiment was performed
with varying concentrations of glucose (0∼40 mmol/L) in 0.1 M PBS. As shown in
Figure 2.4b and 2.4c, similar bell-shaped curves were observed with a maximum value
of ∼27 mmol/L and 23 mmol/L for MGO-GOx + MGO-CPO and MGO-GOx-CPO,
respectively. When β-D-glucose concentration was low, not enough H2O2 can be
released for CPO catalysis. However, high concentrations of glucose are not favorable
for CPO either due to the irreversible in- activation of CPO caused by β-D-glucose [43].
It has been reported that β-D-glucose can result in precipitation of CPO due to its
potential interaction with amino groups and binding to the carbohydrates on the surface
of the protein. This interaction can also result in the fall-off of CPO from the carrier
(CPO immobilized on the carrier only by physical coupling via weak force) and the
decrease of catalytic activity of MGO-GOx-CPO [43]. However, the interaction of
glucose with CPO can be ignored in our experiment because the concentration of
glucose was controlled at a lever below noticeable adverse effect can take place.
Therefore, 27 and 23 mmol/L of glucose were used for the MGO-GOx + MGO-CPO
and MGO-GOx-CPO systems in further studies.
2.3.3 Effects of supporting material on the adsorption of dye
In order to distinguish whether the decolorization is achieved by oxidation or simple
physical adsorption of the dyes on the carrier, the effect of adsorption and desorption
of the dye was investigated (Table 2.1). Orange G was not degraded by the carrier itself.
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Even if the dye was adsorbed on the carrier, the adsorbed dye was actually degraded by
where A1 or A2 is the absorbance at 478 nm before and after adsorption, respectively.
A3 is the absorbance at 478 nm after desorption CPO in the carrier. Therefore, although
the decolorization was due to the combined effects of catalytic oxidation and adsorption,
catalytic oxidation of the enzyme played the dominating role in the observed
decolorization activity of MGO-enzymes.

Table 2.1 Adsorption and desorption rate of dye on the surface of MGO.

2.3.4 Kinetic properties of the immobilized CPO
As expected, the kinetic parameters (Km and Vmax) of free CPO were both changed
after immobilization on different supporting materials (Table 2). Of particular interest,
the Km of immobilized CPO on MGO and MGO-GOx decreased systematically
compared to that of the free CPO. The significant decrease in Km of the immobilized
CPO indicated dramatic increase in the protein’s affinity toward substrate (orange-G),
suggesting either favorable conformational changes in CPO or the advantageous
surface property of the carrier (large surface area and functional groups) that enhanced
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the formation of enzyme-substrate complex upon immobilization. Both Vmax and kcat
for the immobilized CPO on either MGO or MGO- GOx were lower than those of the
free CPO. The decrease in maximum rate and turnover number are anticipated due to
diffusional limitations imposed by the carrier that would result in reduced speed of the
co- substrate, H2O2, to access the active site of CPO immobilized on MGO. Thus, CPO
immobilized on MGO-GOx showed the lowest Vmax and kcat because H2O2 needs to
be generated in situ in MGO-GOx-CPO. Interestingly, the catalytic efficiency (kcat/Km)
of CPO immobilized on either MGO or MGO-GOx was approximately 2.1- and 2.5times higher, respectively, compared to that of the free CPO. The superior catalytic
efficiency of CPO immobilized on MGO-GOx implicates catalytically efficient
encounters of the substrate with CPO in this system is significantly improved, possibly
due to the in-situ generation of H2O2 that eliminates oxidative damage to CPO as a
result of local extreme concentrations of H2O2 in solution. Our results suggested that
use of an enzyme cascade is practical in harnessing the catalytic power of enzymes,
such as cytochromes P450 that require the participation of auxiliary enzymes
(reductases) [44-46].
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Table 2.2 Kinetic properties of free and immobilized CPOa.

2.3.5 Degradation of orange G, acid blue 45 and crystal violet by MGO-GOx-CPO
It is exciting to note that CPO immobilized on MGO displayed significantly
enhanced catalytic activity toward the degradation of all three dyes selected in this study.
As shown in Fig. 5, up to 96.1% Orange G, 97.2% Acid blue 45 and 98.5% Crystal
violet are degraded by MGO-GOx-CPO within 60 min under relatively mild conditions.
It is also worth mentioning that MGO-GOx-CPO effectively decolorized environmental
wastewater contaminated by synthetic dyes as described below.

Figure 2.5 MGO-GOx-CPO catalyzed decolorization/degradation of orange G, acid blue 45
and crystal violet as monitored by UV/Vis spectrophotometry. The insets in the figures show
the color of samples before and after CPO degradation.
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Figure 2.6 Decolorization of orange G with MGO-GOx-CPO in pure buffer and in actual
wastewater with same amount of orange G added (From left to right, orange G in pure buffer
without treatment, and orange G in water samples from Hei river, Fengyu, Qinzhen and a
man-made lake after treatment).

The decolorization of Orange G (0.125 mmol/L) in wastewater by MGO-GOx-CPO
was shown in Figure 2.6. The decolorization efficiency of Orange G reached 93.4% in
Hei river, 92.2% in Fengyu, 90.3% in Qinzhen, and 87.8% in a man-made lake,
respectively. The decrease of decolorization efficiency in real wastewater samples was
possibly due to the presence of multiple metal ions and microorganism in the samples
that would interfere with the performance of CPO.
2.3.6 Thermal stability of CPO
Most catalytic reactions in industry are carried out under conditions unsuitable for
naturally occurring enzymes. For example, running reactions at elevated temperature is
a common practice to accelerate reaction rate, increase solubility, reduce solution
viscosity, and avoid microbial pollution. This precludes the industrial application of
many enzymes due to their limited thermal stability. Immobilization on suitable
supports offers a novel revenue to improve the thermal stability of the enzymes, making
their large-scale industrial application possible.
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2.3.6.1 Thermal stability of CPO from 20 °C to 70 °C
Temperature is a critical factor that affects the decolorization of orange G by both
free and immobilized CPO. Figure 2.7a show the thermal stability of free and
immobilized CPO expressed as residual activity after incubation at different
temperatures (from 20 °C to 70 °C). In general, the stability of MGO-CPO differs
notably from that of free CPO. When reaction temperature is increased to 70 °C, free
CPO kept only about 10% of its initial activity, while MGO-CPO retained
approximately 30% of its initial activity within one hour.

Figure 2.7 Thermal stability of free and immobilized CPO (a) at different temperatures and
(b) at 50 °C as a function of time.

The thermal stability of CPO was different for the three immobilization systems
designed. On one hand, MGO-GOx-CPO was superior to the combination of MGOGOx and MGO-CPO, probably due to mass transfer resistance between GOx and CPO
experienced in the latter case. As shown in Figure 2.8a, when GOx and CPO were
individually immobilized on the surface of MGO, the oxidation of β-D-glucose was
catalyzed by GOx in the presence of O2 to produce H2O2 in situ, which was used as the
oxidant by the nearby CPO for the degradation of dyes. The catalysis will be improved
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if the H2O2 produced can reach CPO and the dye substrate quickly. This explains the
fact that the amount of oxidant was not always proportional to the observed activity of
CPO. The advantage of in situ production of H2O2 in MGO-GOx-CPO is a critical
factor in determining the operational stability and catalytic efficiency of CPO. In
addition, there is no mass transfer resistance between CPO and GOx compared to the
combination of MGO-GOx and MGO-CPO, allowing the H2O2 produced in situ to be
directly used for the effective transformation of substrates (Figure 2.8b).

Figure 2.8 (a) Mass transfer resistance between CPO and GOx for MGO-GOx + MGO-CPO;
(b) no mass transfer resistance between CPO and GOx for MGO-GOx-CPO.

2.3.6.2 Thermal stability of CPO at 50 °C
The thermal stability of free and immobilized CPO at 50 °C is shown in Figure 2.7b.
As can be seen, the stability of CPO was significantly improved after immobilization.
The immobilized CPO retained more than 60% of its initial activity after10 h incubation
at 50 °C, while free CPO completely lost its activity under identical conditions.
Immobilized CPO on MGO-GOx resulted in the highest stability. This is due, in part,
to the improved enzyme rigidity associated with immobilization [47] and in part to the
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in situ production of H2O2 that avoids the oxidative in- activation of CPO caused by
local extreme concentrations of H2O2.
It should be noted that the thermal stability of CPO immobilized on MGO
composites was not only much better than free CPO but also superior to CPO
immobilized on other supports pioneered by other groups [47-50]. In practice,
formation of multi point interactions between enzymes and MGO composites may
stabilize the weak intramolecular forces [47].
Moreover, the GO layers will naturally stack due to the presence of Fe3O4 in MGO.
This makes it difficult for some enzyme molecules to play an effective catalytic role. It
is worth mentioning that the activity of MGO-GOx-CPO displayed a somewhat strange
relationship with the reaction temperature as shown in Figure 2.7a. Different from a
consistent decrease in activity with increasing temperature as observed with free CPO,
the activity of MGO-GOx-CPO initially decreased as temperature was increased.
However, when temperature reached a critical point around 42 °C, the activity of MGOGOx-CPO started to increase and remained high until temperature reached 50 °C. This
unusual phenomenon could be attributed to the re-dispersion of the stacked MGO layer
due to thermal diffusion (Figure 2.9) as revealed by SEM images (Figure 2.10). The
dispersion of the stacked MGO layers override the adverse effect of increasing
temperature, accounting for the good thermal stability of CPO immobilized on MGO
between 42 and 50 °C. However, as temperature went above 50 °C, the adverse effect
of increasing temperature superseded the beneficial effects from dispersion of the
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stacked MGO layers, therefore the activity of MGO-GOx-CPO decreased as
temperature was further increased.

Figure 2.9 The GO layers are dispersed due to thermal diffusion.

Figure 2.10 SEM images of the GO dispersed layers at 20 °C (a) and 50 °C (b).
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2.3.7 Reusability of MGO-GOx + MGO-CPO and MGO-GOx-CPO
The reusability of immobilized CPO on different systems is shown in Figure 2.11.
CPO co-immobilized with GOx (MGO-GOx-CPO) shows a relatively good reusability
with more than 38.5% residual activity retained after 6 cycles of use for the oxidation
of the dyes. Consistent with enzymes immobilized on most supporting materials [51,
52], the activity of MGO-GOx-CPO decreased after each recycle, possibly due to
enzyme fall off from the carrier. Nonetheless, the magnetic nature of GO composite
particles allows easy separation of the immobilized CPO from the reaction mixture,
making the reuse of CPO feasible.

Figure 2.11 MGO-CPO displays significantly improved reusability in catalysis.
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2.4 Conclusion
A new type of composites (GO-Fe3O4) with the combined ad- vantages of large
surface area of GO and magnetic property of Fe3O4 was synthesized to serve as supports
for the immobilization of CPO and GOx-CPO. The immobilized CPO exhibits
enhanced operational dur- ability, thermal stability, catalytic efficiency, and reusability.
in particular, MGO-GOx-CPO, showed far greater thermal stability than the free
enzyme. MGO-GOx-CPO not only reduce the mass transfer resistance between the two
enzymes, but also allow the production of H2O2 in situ. Taken together, our results
presented herein demonstrated that GO functionalized by Fe3O4 is a great support for
the co-immobilization of CPO with GOx. This material might also find applications in
the assembly of robust biological catalysts composed of other enzyme systems such as
cytochromes P450 for the synthesis of fine chemicals and degradation/removal of
synthetic dyes and other pollutants from industrial wastewater.

37

CHAPTER III.
MECHANISMES OF CHLOROPEROXIDASE-CATALYZED
ENANTIOSELECTIVE EPOXIDATIONS--A NUCLEAR
PARAMAGNETIC RELAXATION STUDY
3.1 Background
The characterization of CPO-substrate complex will be carried out using UV-Vis
spectrophotometry and nuclear magnetic resonance (NMR) spectroscopy. We will focus
on understanding the mechanism of CPO-catalyzed enantioselective epoxidation and
structure-activity relationship of CPO. As we know, this mechanism also represents
synthesis featuring enantioselective epoxidation moderated by chloroperoxidase.
Because of chloroperoxidase’s ready availability, ease of use, and potential for high
selectivity, its use in the synthesis of intermediates difficult to obtain by other methods
is a continuing investigation in my research [53]. So, to investigate the mechanism of
CPO-catalyzed reactions remains mysterious and its application will be ringing rapid
and effective development in industry. The project will investigate the structural factors
that contribute to CPO’s stereoselectivity in catalyzing epoxidation reactions.
Chloroperoxidase from the marine fungus Caldariomyces fumago has been the
subject of extensive studies due to its versatile catalytic activities and potential
biotechnological applications such as synthetic chemistry, pharmaceutical industry, and
environmental management. Chloroperoxidase catalyzes a broad spectrum of chemical
reactions including the traditional oxidation activity typical of classical peroxidases,
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dismutation reaction of catalase, epoxidation of olefin by cytochrome P450
monooxygenases,

and

halogenation/dehalogenation

reactions

unique

to

haloperoxidases. Most significantly, CPO-catalyzed oxidation and epoxidation
reactions proceed with high regio- and enantio-selectivity. Great efforts have been made
during the past several decades aimed at understanding the mechanism of CPO’s regioand/or enantio-selectivity [114]. It has been generally agreed that most enzyme
catalyzed chemical transformations proceed via the formation of enzyme-substrate
complexes. Therefore, understanding the structural features of the CPO-substrate
complexes will undoubtedly cast fresh light on the structure-function relationships of
heme peroxidase in general and the structural basis for the broad catalytic activity, strict
substrate specificity, and high regio-/enatio-selectivity exhibited by CPO in particular.
The definitive structure of CPO-substrate complexes will also provide crucial
information regarding the topology of the heme active site of CPO, the critical residues
involved in catalysis, the location as well as orientation of substrate within/near active
site, and eventually, the mechanisms of CPO-catalyzed regio-/enantio-selective
reactions. The information extracted from such studies can serve as a lighthouse in the
design of more efficient CPO mutants that target specific substrates and produce custom
products that are difficult to obtain with traditional organic synthesis under mild
conditions. Unfortunately, the structural information about CPO-substrate complexes
remains surprisingly scarce despite the great efforts made during the past few decades
with the application of the most powerful techniques available such NMR spectroscopy
and X-ray crystallography.
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It is generally believed that X-ray crystallography is the most authoritative
techniques for establishing the three-dimensional structure of proteins and proteinsubstrate complexes. The crystal structure of CPO resolved by Poulos and coworkers
has demonstrated the presence of a substrate-binding site with a channel above the heme
that enables access of organic substrates to the oxoferryl oxygen of CPO compound I
[46]. It is well known that substrate binding would result in noticeable structural
rearrangements of the protein. Contrary to this general agreement, the structures of
CPO-ligand complexes are indistinguishable from that of the ligand-free protein.
Furthermore, the crystal structure of CPO complexed with its natural substrate, 1,3cyclopentanedione (CPDO), (PDB code: 2CIX) revealed another astonishing scenario
in that the active methylene group of CPDO is not pointing towards the heme iron. This
structure is actually in good agreement with the results reported from an NMR
relaxation study of CPO-CPDO complex in solution. To my knowledge, 2CIX is the
only crystal structure of CPO complexed with a substrate. The limited structural data
on CPO-substrate complexes is mainly the result of the difficulty of diffusing organic
substrates into CPO crystals as explained[115].
Nuclear magnetic resonance (NMR) spectroscopy is an alternative technique to Xray crystallography for investigating the structural information of enzymes and their
complexes with substrates in solution. Especially, in heme proteins, the enhanced
nuclear relaxation induced by the paramagnetism of the heme can be successfully used
to deduce the structure and stability of enzyme-substrate complex. Many reports in
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literature have demonstrated that NMR relaxation studies can be used in extracting the
structural features of CPO complexed with different classes of substrates, for example,
phenols [116], sulfides [117], and the natural chlorination substrate, CPDO [118].
Along with the advances in computational chemistry, molecular mechanics studies
have become a popular complement to NMR and X-ray studies in understanding heme
proteins and their interactions with substrates at the atomic level [114]. For solution
studies, distances between substrate and the heme iron of protein can be determined by
NMR measurements. The distance obtained can be used as restraints in simulation
studies using a simulated annealing protocol. The simulation method has been
successfully applied to the investigation of substrate binding to several hemoproteins
[119]. The success of these studies has encouraged us to undertake this project of
investigating the mechanisms of CPO-catalyzed enantioselective epoxidation of a few
selected olefins (Figure 3.1) using both NMR and computational techniques.
The CPO-catalyzed epoxidation of the olefins chosen for this study was first reported
in by Hager and his coworkers in 1996 [120]. It is noted that the epoxidation of these
structurally closely related olefins yields the corresponding epoxides with strikingly
different enantioselectivity. The reactivity of the olefins also varies depending on the
nature and the position of substituents along the double bond. However, to our best
knowledge, the structural basis for CPO-catalyzed enantioselective epoxidation of
substituted olefins remains undefined. Therefore, a detailed structural characterization
of CPO-olefin complexes would offer fresh insight into the mechanisms of CPO-
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catalyzed epoxidations and solve the long-lasting mystery of the dramatically different
product distribution from epoxidation of these structurally closely related olefins.
The aims of the present work are to reveal the orientation of the selected substituted
olefin binding at the active site of CPO, to identify the residues involved in the
formation of CPO-olefin complex, and to elucidate the mechanism of CPO-catalyzed
enantioselective epoxidation of olefins. The interaction of the substituted olefins with
CPO was probed using longitudinal NMR relaxation and two computational methods,
molecular docking and simulated annealing. The dissociation constant of CPO-olefin
complex and the distances between the protons of olefin and the heme iron of CPO are
obtained. The effect of pH and halide ion on the binding of olefin with CPO is also
inspected. Simulated annealing and molecular docking of the substituted olefins in the
active center of CPO are provided. Our results showed that a complex with a KD of
approximately 21 mM is formed between CPO and the selected olefins with 3-H of the
olefin pointing towards the heme iron. The simulation structural feature satisfactorily
explains the unusual product observed from CPO-catalyzed epoxidation of the selected
olefins. It is concluded that formation of CPO-olefin complex is responsible for the
escorted delivery of oxygen from CPO compound I to the preferred side of the double
bound in the substituted olefins, resulting in the observed enantioselectivity in product
distribution.
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3.2 Materials and Methods
3.2.1 To estasblish the three-dimensional structure of the complexes formed
between CPO and some selected substrates
Structural similarity of some known substrates compared to their dramatically
different stereochemistry of the corresponding products serviced as our guideline in the
selection of the substrates used for this study. Specifically, we will use ethyl 3methylbut-3-enoate (L-1), 2-methylallyl propionate (L-2), and ethyl 3-methylbut-3enoate (L-3) (Figure 3.1) as substrates to investigate the mechanism of CPO catalyzed
epoxidations. NMR and UV-Vis spectrophotometry will be used to detect the formation
and characterization of CPO-substrate complexes.

Figure 3.1 The substrates selected for this project

3.2.2 Caldariomyces fumago’s Expression and Purification
A piece of the colonized acrylamide plates was cut and inoculated in a 250-mL flask
at 25 °C (the optimal temperature for CPO expression) and 250 rpm for 5 days (Figure
3.2). Different assays, described in the later section, was used to monitor the status of
CPO production. The 250-mL cultures was transferred to the 2-L flask and incubated
at 25 °C and 250 rpm for 5 more days. Afterward, acetone precipitation was used to
separate protein from impurities [53]. The filtrate was concentrated to 30 mL through
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an Amicon high pressure cells using a membrane of 30 kDa cutoffs. After concentrating
the medium containing CPO, the sample was dialyzed against 4 L buffer A (25 mM
phosphate buffer, pH 5.9) overnight with at least one-time change of buffer. The
dialyzed CPO was filtered through a 0.45 μm filter and subjected to two types of
chromatography, ion-exchange and size exclusion [54]. For ion-exchange, the column
was packed with diethylaminoethanol (DEAE) sepharose and equilibrate with buffer A.
The protein was loaded onto the column and washed with buffer A. Elution was done
by gradually increasing NaCl concentration (0-0.5 M) of the buffer. When the protein
elutes, a red color was seen. Eluted fractions with Reinheitzahl (Rz, A398/A278) values
above 1.0 were combined and concentrated to approximately 1 mL through a Millipore
centrifugal filter unit (30,000 Da cutoff)). The concentrated sample will be purified
through a size exclusion column packed with Sephadex G75 resin and washed with
buffer A. Similarly, the eluted fractions with the highest Rz-value was combined and
concentrated for use in substrate binding experiments.

Figure 3.2 Chloroperoxidase’s expression and purification
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3.2.3 MCD Assay
The MCD assay is commonly used for determining the chlorination activity of
chloroperoxidase [55]. The assay monitors the chlorination of monochlorodimedone
(MCD) to dichlorodimedone (Figure 3.3). The reaction system composed of CPO in
100 mM potassium-phosphate buffer containing 20 mM KCl and 0.17 mM MCD (pH
range 2.5- 5.0). The reaction was initiated by the addition of 2.2 mM H2O2 and the rate
of chlorination was monitored at 278 nm where MCD absorbs.

Figure 3.3 Enzyme Activity Assay (MCD Assay)

3.2.4 Synthesis and Characterization of the Selected Compounds
As outlined in Scheme 1, esterification of 2-methyl-2-propen-1-ol with propionic
anhydride afforded compound L-1. Using the same condition, compound L-3 was
synthesized by esterification of 2 methyl-2-propen-1-ol with acetyl anhydride as shown
in Scheme 3. To synthesis compound L-2, 3-methyl-3-buten-1-ol was oxidized with
Jones reagent and esterified with ethanol as depicted in Scheme 2. The yield of this
route is higher than that of the Wittig reaction and esterification from the material 3oxobutanoic acid. Detailed synthesis procedure is described below.
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Scheme 1, conditions and reagents used for the synthesis of L-1: a) pyridine,
dichloromethane, 40ºC, 8~9h, yield: 90%

Scheme 2, conditions and reagents used for the synthesis of L-2: a) Jones reagent,
acetone, 0 ºC, 1h, yield: 86%; b) ethanol, methanesulfonic acid, 70 ºC, 2h, yield: 31%

Scheme 3, conditions and reagents used for the synthesis of L-3: a) pyridine,
dichloromethane, 40 ºC, 8~9h, yield: 81%
To the solution of 2-methyl-2-propen-1-ol (50.0g, 0.693 mol), propionic anhydride
(108g, 0.832 mol), dichloromethane (1L) at 0 ℃ , the pyridine (109g, 1.38 mol)
dissolved in 100 ml dichloromethane was added dropwise. The mixture was reacted for
8~9 h at 40 ℃. After the reaction, monitored by TLC (petroleum ether/AcOEt = 3:1),
was completed, the mixture was extracted by 4 mol/L HCl solution (400 mL ×10),
washed by saturated sodium bicarbonate solution (400 mL ×7), water (400 mL ×2),
saturated brines (400 mL ×2) and dried by anhydrous sodium sulfate. After filtration,
evaporation and distillation, the final production was obtained as a clear, colorless oil
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80.0g (90%). Proton NMR (Figure 3.4) analysis confirmed the identity of the product.

Figure 3.4 Proton NMR spectra of 2-methyl-2-propen-1-ol. H NMR (300 MHz, DMSO-d6) δ
4.90~4.86 (2H, d, J=12.0Hz, -C=CH2), 4.43 (2H, s, -O-CH2-), 2.37~2.26 (2H, q, J1=7.5Hz,
CH3-CH2-CO-), 1.67 (3H, s, CH3-C=CH2), 1.02 (3H, t, J=7.5 Hz, CH3-CH2-CO-) ppm.

Compound L-2 was obtained following the following procedure. To the solution of
3-methyl-3-buten-1-ol (10 mL, 0.099 mol) and acetone 500 mL at 0 ℃, the Jones
reagent (52 mL, 0.138 mol) was added dropwise. The reaction was stirred for 1h at
0 ℃. After the reaction, monitored by TLC, was complete, the 2N NaOH solution was
added and stirred for 30min. then, the mixture was adjusted by 4 mol/L HCl solution to
pH of 3~4, extracted by diethyl ether (300 mL ×7), washed by saturated brines (300 mL
×2) and dried by anhydrous sodium sulfate. After filtration, evaporation, and distillation,
the intermediate of 3-methyl-3-butenoic acid was provided as a clear, light yellow oil
10.3g (86 %). The mixture of 3-methyl-3-butenoic acid (5g, 0.05 mole) and methane
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sulfonic acid (1 mL) in ethanol (30 mL) was stirred for 2 h at 70 ℃. After the reaction,
monitored by TLC, was complete, the mixture was extracted by n-pentane (50 mL ×5),
washed by water (50 mL ×5), saturated brines (50 mL ×5) and dried by anhydrous
sodium sulfate. After filtration, evaporation and distillation, the product was obtained
as a clear, light yellow oil with a total of 2.01g (31 %) as confirmed by proton NMR
analysis (Figure 3.5).

Figure 3.5 Proton NMR spectra of 2-methylallyl propionate. H NMR (300 MHz, DMSO-d6) δ
4.86~4.82 (2H, d, J=10.0 Hz, -C=CH2), 4.11~4.04 (2H, q, J1=7.11 Hz, CH3-CH2-O-), 3.04 (2H,
s, -CO-CH2-), 1.74 (3H, s, CH3-C=CH2), 1.19 (3H, t, J=7.11 Hz, CH3-CH2-O-) ppm.

The following procedure was employed to synthesize compound L-3. To the solution
of 2-methyl-2-propen-1-ol (25.0g, 0.290 mol), acetic anhydride (37.6g, 0.348 mol),
dichloromethane (300 mL) at 0 ℃, the pyridine (45.8g, 0.580 mol) dissolved in 50 mL
dichloromethane was added dropwise. The mixture was reacted for 8~9 h at 40 ℃.
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After the reaction, monitored by TLC (petroleum ether/AcOEt = 3:1), was complete,
the mixture was extracted by 4 mol/L HCl solution (200 mL ×10), washed by saturated
sodium bicarbonate solution (200 mL ×7), water (200 mL ×2), saturated brines (200
mL ×2) and dried by anhydrous sodium sulfate. After filtration, evaporation and
distillation, the final product was obtained as a clear, colorless oil with a total yield of
31.3g (81%). The structure of the product was confirmed with proton NMR analysis as
shown in Fig. 3.6.

Figure 3.6 Proton NMR spectra of 3-methylbut-3-en-1-yl acetate. H NMR (300 MHz, DMSOd6) δ 4.78~4.72 (2H, d, J=17.1Hz, -C=CH2), 4.11 (2H, t, J=6.7 Hz, -O-CH2-CH2-), 2.31 (2H, t,
J=6.7 Hz, -O-CH2-CH2-), 1.98 (3H, s, CH3-CO-), 1.71 (3H, s, CH3-C=CH2) ppm.

3.2.6 NMR relaxation of the CPO-substrate Complexes
Proton NMR relaxation measurements were conducted on a Bruker Avance 600
MHz NMR spectrometer at 298.0 K. The NMR data were processed using Topspin,
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version 2.1.The longitudinal relaxation time (T1) was determined using the standard
inversion-recovery method with 180°-τ-90° pulse sequence [56]. Eleven spectra were
recorded for each sample, with the inter-pulse delay τ ranging from 0.05 to 10.0 s. For
each spectrum, 16 scans were acquired. The T1 values were calculated by fitting
Equation 3.1, where τ is the interval between 180° and 90° pulses, Mz is the Zcomponent of nuclear magnetization (represented by the intensity of the peak) when
the interval is τ, M0 is the is the Z-component of the nuclear magnetization when the
interval is infinite, and ρ is a parameter that equals to 2.0 at an exactly 180° pulse.

(3.1)
The samples used for NMR experiments contained 2-10 mM substrates and 0.1 mM
CPO in 100 mM phosphate buffer with 99.9% D2O. The final volume of all NMR
samples was 500 L.
3.2.7 Dissociation constants of CPO- L-2 complex
The longitudinal relaxation rate (T1obs-1) is the weighted average of the relaxation
rates of the free substrate (T1f-1) and the bound substrate (Tb-1) [57]. Thus, the
relaxation-time values (T1obs-1, T1f-1, and Tb-1) are related as shown in Equation 3.2 when
only one molecule of substrate binds to a molecule of enzyme, where T1obs is the
relaxation time of the substrates obtained from the relaxation experiment, T1f is the
relaxation time of substrates obtained from the relaxation experiment in the absence of
CPO, T1b is the relaxation time of the CPO bound substrates, KD is the dissociation
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constant of CPO substrates complex, E0 is the initial CPO concentration, and S0 is the
initial substrates concentration.

(3.2)

3.3 Results & Discussion
3.3.1 Proton NMR spectrum of substrate L-2 in the presence of chloroperoxidase
(CPO)
The H-NMR spectra of 5.0 mM substrate L-2 in the absence and presence of varying
amount (0.01, 0.05, 0.08, 0.1, and 0.15 mM) of CPO is shown in Figure 3.8. The five
main peaks can be easily assigned, based on the splitting pattern and shift positions, to
the protons of the substrate L-2 in the absence of CPO (Figure 3.7) 1.19 ppm (1-H),
4.11 ppm (2-H), 3.04 ppm (3-H), 1.75 ppm (5-H). The 4-H was not observed due to
overlap with the large peak of H20.
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Figure 3.7 The structure of substrate L-2, proton number assignment is shown. 1.19 ppm (1H), 4.11 ppm (2-H), 3.04 ppm (3-H), 1.75 ppm (5-H).

As the concentration of CPO increased from 0.01 to 0.15 mM, the linewidth of the
1- proton increased from 21.73 to 27.89 Hz (Figure 3.8). The linewidth of 3-H also
increased dramatically from 10.75 to 17.05 Hz as the concentration of CPO was
increased. In contrast, the other peaks were less broadened than those of the 1- and 3H. For instance, the linewidth of 2-H increased gradually from 27.43 to 30.35 Hz in the
range of the CPO concentration tested. The shorter distances suggests that protons 1-H
or 3-H are closer to the heme iron than other protons of the substrate.

Figure 3.8 The effect of the concentration of CPO on the proton NMR spectra of substrate L2. The spectra were obtained in 100 mM deuterated phosphate buffer (pH 5.9) containing 5.0
mM L-2 and varying concentrations of CPO.

3.3.2 Dissociation constant of CPO- L-2 complex
To evaluate the binding affinity between CPO and L-2, the longitudinal relaxation
time (T1) of L-2 protons was measured in the presence of 0.1 mM CPO and different
concentrations of L-2 (2.0-10.0 mM) at pH 5.9. Figure 3.9 shows the exponential fit of
signal intensities (Mz) as a function of the delay time () as defined in Equation 3.1,
using the resonance at 1.19 ppm (1-H) as an example. Similar fits are obtained for other

52

protons of L-2. Therefore, T1obs of 1-H (Figure 3.9A-E) can be obtained from Equation
2.1 (2.38s, 2.58s, 2.75s, 2.89 s, and 3.05s, respectively). The increase in T1obs is
attributed to the increase of the fraction of free L-2 as its concentration is increased as
show in a plot of E0[1/T1obs – 1/T1f]-1 versus S0 for 1-H. The fitted straight line
demonstrates the reliability of the data (R2=0.9741). The KD value can be calculated as
the intercept of the fitted line divided by its slope using Equation 3.2. The KD calculated
from Figure 3.9F was approximately 16 mM.(2-H is 6 mM, 3-H is 22 mM, 5-H is 32
mM)

Figure 3.9 NMR relaxation experiments for 1-H of substrate L-2 in the presence of CPO. (AE) The results were obtained in 100 mM deuterated phosphate buffer (pH 5.9) containing 0.1
mM CPO and (A) 2.0 mM·L-2, (B) 4.0 mM·L-2, (C) 5.0 mM·L-2, (D) 8.0 mM·L-2, and (E) 10.0
mM·L-2. (F) The plot of E0[1/T1obs – 1/T1f]-1 as a function of the concentration of L-2 (S0).
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3.3.3 Distances between CPO Heme Iron and the Protons of L-2
To reveal the orientation of L-2 in the active site of CPO, paramagnetically induced
NMR relaxation of L-2 in the presence of CPO was used to calculate the distance
between the heme iron and the protons of L-2. Table 3.1 lists the NMR relaxation time,
T1b, and the calculated distances between the protons of L-2 and the heme iron of CPO.
These distances are consistent with those obtained for alky phenyl sulfides (8.0-10.9
Å), phenols (5.6-9.3 Å), CPDO (7.1 Å), and L-2 binding with CPO. Examination of
Table 3.1 revealed that the distance between the heme iron of CPO and proton 3 of L2 is the shortest. This position happens to be the location at which the epoxidation takes
place, indicating that the epoxidation of L-2 proceeds by a direct insertion of oxygen
from the oxyferryl intermediates of CPO to the double bond of the olefin. Furthermore,
the use of these distance constraints in advanced computational methods such as
simulated annealing can provide the precise orientation and position of L-2 in the active
site of CPO, which will be presented in Distance-Restrained Model of CPO Complexed
with L-2.
Table 3.1. The dissociation constant (KD) of CPO-L-2 complex and the distances
(r) between the protons of L-2 and CPO heme irona
position

δ (ppm)

T1b (s)

r (Å)

KD (mM)

2-H

4.07

2.2x10-3

9.0

6

3-H

3.04

1.9x10-4

6.6

22

5-H

1.74

2.6x10-3

9.8

32

1-H

1.19

2.7x10-2

11

16

a

The relaxation experiments were performed in 50 mM deuterated phosphate
54

buffer (pH 5.9) 0.1 mM CPO by changing the concentration of L-2 from 2 to 10 mM.

Figure 3.10 Distance-restrained model of L-2 in the active site of CPO, to differentiate
the protein residues from the substrate, the L-2 molecules are colored green, the oxygens are
colored red.

On the basis of our docking results (Figure 3.10), the distance of 1-H was 11 Å, the
2-H was 9 Å and the 5-H was 9.8 Å from the hem iron center. The lowest energy results
are also matched to the NMR relaxation measurements, with 3-H (6.6 Å) being the
closest to the heme iron.

Figure 3.11 Distance-restrained model of L-2 in the active site of CPO.

To
differentiate the protein residues from the substrate, the L-2 molecules are colored
green, the heme is colored brown, and the carbons of the residues are colored blue.
It is observed that residues close of L-2 are PHE103, PHE186, VAL182, ILE179,
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LEU70, ALA71. Week forces between L-2 and these residues in CPO help to stabilize
the complex formed between CPO and L-2, orienting L-2 in a position ensuring the
formation of the observed enantioselectivity in production distribution.
3.4 Conclusion
The work presented here provides insights into the mechanism of the CPO-catalzyed
enantioselective oxidation of L-2. Association of L-2 with CPO was confirmed from
both linewidth and longitudinal relaxation time measurements of the proton NMR
signals of L-2. Based on the dissociation constant (KD) of CPO L-2 complex at pH 5.9,
the KD values obtained from the relaxation property of different protons in L-2 are quite
consistent, further proving the validity of the relaxation method in probing the structural
properties of hemoprotein-substrate complexes.
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CHAPTER IV.
RATIONAL MODIFICATION OF DANOFLOXACIN INTRODUCES NOVEL
ANTICANCER ACTIVITY
4.1 Background
4.1.1 Development of lung cancer treatment
Lung cancer is one of the most common cancers and the leading cause of cancerrelated deaths worldwide. Due to the lack of clinical symptoms and effective screening
programs, most lung cancer is diagnosed in the advanced stage. However, the treatment
and prognosis of lung cancer depend on accurate staging of the disease [58, 59]. Nonsmall cell lung cancer (NSCLC), which includes adenocarcinoma (glandular formation),
squamous cell carcinoma, and large cell carcinoma tissue subtypes, accounts for
approximately 85% of all new lung cancer cases [60]. Lung cancer accounts for more
than 1.8 million new cancer diagnoses worldwide each year (13% of all cancer
diagnoses) and 1.6 million cancer-related deaths (19.4% of the total) [61]. In the United
States, there were an estimated 224,210 new lung cancer cases and 159,260 deaths in
2014. In Europe, there were an estimated 410,000 new lung cancer cases and 353,000
deaths in 2012 [62]. While lung cancer rates are falling in developed countries, they are
rising in less developed parts of the world (Africa, South America, eastern Europe and
China). In fact, 58% of the 1.8 million new cases worldwide in 2012 occurred in
underdeveloped regions. One possible explanation for the findings is that smoking rules
in these countries are less strict. However, lung cancer rates are highest in North
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America, Europe, Australia, New Zealand and China [63]. Despite recent advances in
therapeutic regimen, the curative effect is not so inspiring because of the poor outcome
[64]. Consequently, it is indispensable to develop more effective therapies against lung
cancer.

Fiugre 4.1 Annual incidence of lung cancer per 100,000 people [60].

4.1.2 Bim-mediated apoptosis in cancer cells
There are two major apoptosis pathways, the extrinsic and intrinsic (mitochondriaassociated) pathways, in cytoplasm. Intrinsic apoptosis could be regulated via
mitochondrial pathway characterized by the release of cytochrome c (Cyt c) and
activation of caspase [65]. The Bcl-2 family proteins, anti-apoptotic proteins (such as
Bcl-2 and Bcl-xL), pro-apoptotic proteins (such as Bax and Bak), and Bcl-2 homology
3-only (BH3-only) proteins (such as Bim, Bad and Puma), play a crucial role in intrinsic
apoptotic process. The apoptotic stimuli activate specific BH3-only proteins to engage
anti-apoptotic proteins and release downstream pro-apoptotic proteins, leading to
increased mitochondrial outer membrane permeability and eventually cell death
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induced by triggering caspase cascade [66]. Subsequently, cytochrome c is released
from mitochondria into cytoplasm which can trigger the caspase cascade, leading to
cell death. Bim acts as direct activators of Bax and Bak by interacting with them. Bim
is also involved in p53-dependent and p53-independent apoptosis [67]. Recent studies
have implicated that Bim may serve as a potential target for anti-cancer
chemotherapeutics since it plays an important role in apoptosis [68, 69].

Fiugre 4.2 Interactions among Bcl-2 family proteins [70].

4.1.3 Transcriptional outputs of FoxO activity
The FOXO subfamily of transcription factors is evolutionarily conserved, including
FOXO1, FOXO3a, FOXO4, and FOXO6 [71]. FOXO proteins can regulate multiple
target genes involved in tumor suppression, such as Bim, FasL, p27kip1, cyclin D and
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GADD45 [72-75]. FOXO3a, the most important transcription factor in FOXO family,
was phosphorylated by Akt at Thr32, Ser253 and Ser315, leading to FOXO3a
translocate from nucleus to cytoplasm and is consequently degraded by proteasome
[76]. The proteasome inhibitor MG132 increases the stability of FOXO3a and induces
apoptosis in thyroid cancer cell [77]. In addition, studies have reported that FOXO3a is
a substrate for autophagy [78]. This suggests that FOXO3a degradation depends not
only on the proteasome pathway, but also on autophagy activation.

Fiugre 4.3 Increased FoxO activity participates in several cellular processes [79].

4.1.4 A modified danofloxacin LZ101 with potential anticancer activity
LZ-101 is a derivative of danofloxacin that has been developed specifically for
veterinary use [80]. Danofloxacin has been widely used for the treatment for respiratory
disease and urinary tract infections in animals, such as chicken and buffalo [81, 82].
However, studies have shown that danofloxacin induces apoptosis by inducing
oxidative stress in renal tubular cells, epithelial cell line (LLC-PK1). This study showed
that danofloxacin exhibited apoptosis-inducing effects. While the effect of danofloxacin
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derivative LZ-101 on apoptosis is still unclear. This study demonstrated that LZ-101
induced apoptosis in A549 human non-small cell lung cancer cells and inhibited tumor
growth with low systemic toxicity in BALB/c mice bearing A549 tumor through
mitochondria-associated pathway by stabilizing FOXO3a via blocking autophagy flux.
Our results showed that LZ-101 exhibits remarkable anti-tumor activity and is
promising to serve as an effective candidate for the treatment of human non-small cell
lung cancer.
4.2 Materials and Methods
4.2.1 Rationale of the modification
DNA topoisomerase I (Top I) is an important enzyme for tumor growth. Traditional
Top I inhibitors, such as the natural alkaloid camptothecin (CPT), can bind and stabilize
a binary DNA-Top I complex containing a single-strand nick, thus inhibiting DNA
replication and eventually causing cell death. Despite the initial success of CPT in
preclinical studies, the low water-solubility of CPT severely limits its use. Therefore,
tremendous efforts have been made to develop more water-soluble analogues of CPT,
such as topotecan (TPT) and irinotecan, which are derivatives of 10hydroxycamptothecin (HCPT) and have been approved for clinical treatment of cancer
patients. However, the therapeutic potential of CPT and its derivatives is severely
hampered by their rapid deactivation by lactone ring hydrolysis at physiological pH. In
addition to CPT and its derivatives, metabolically stable non-CPT derivatives, such as
indolocarbazoles and indenoisoquinolines, have been developed, some of which are
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under clinical evaluation. Given the success of these non-CPT derivatives, we believe
that non- CPT Top I inhibitors have better chemical stability because they lack a lactone
ring in their skeleton. We attempted to synthesize compounds lacking CPT lactone ring,
and converted the rigid framework of CPT into the single bond binding of quinolones
and benzimidazole groups. Therefore, we modified danofloxacin to synthesize its
derivative LZ101, and to study the anti-tumor effect of LZ101.
4.2.2 Structural Characterization of the Modified Danofloxacin--LZ101
We kept the main group of danofloxacin, including the basic structure of 4-oxoquinoline, the 2,5-Diaza-bicyclo[2.2.1]heptane, the fluorine atom, and the ternary
carbon ring on the nitrogen atom. The carboxyl group at the C-3 position was modified
into cyanosubstituted benzimidazole to improve the activity.

Figure 4.4 The molecular structure of LZ-101.

4.2.3 In-vitro Study
4.2.3.1 Cell culture
Human non-small cell lung cancer cell line H460 and H1299 cells were cultured in
RPMI-1640 medium (Gibco, Waltham, USA) and A549 cells were cultured in F-12
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medium (Gibco, Waltham, USA) supplemented with 10% fetal bovine serum (Gibco,
Waltham, USA), 100 U/ml penicillin and 100 U/ml streptomycin, cells were cultured
in a humidified CO2 (5%) incubator (Thermo Forma, Waltham, USA) at 37 °C.
4.2.3.2 MTT assay
Experiments were done in triplicate in a parallel manner for each concentration of
LZ-101 used and the results are presented as mean ± SEM. Control cells were given
culture media containing 0.1% DMSO. After incubation for 24 or 48 h, 20 μL of 5
mg/mL MTT was added to cells, and cells were incubated at 37 °C for another 4 h. The
absorbance (A) was measured at 570 nm using an ELx800 automated microplate reader
(BioTek Instruments, Inc.). The inhibitory ratio (%) was calculated using the following
equation: inhibitory ratio (%) = (1- average absorbance of treated group / average
absorbance of control group) × 100%. IC50 was taken as the concentration that caused
50% inhibition of cell viability and was calculated by the Logit method.
4.2.3.3 Annexin V/PI staining
A549 cells were harvested, washed, and resuspended in PBS after LZ-101 treatment,
then stained with the Annexin V/PI Cell Apoptosis Detection Kit (KeyGen Biotech,
Nanjing, China) according to the manufacturer’s instructions. Data acquisition and
analysis were performed with a Becton Dickinson FACS Calibur flow cytometer using
Cell-Quest software (BD Biosciences, Franklin Lakes, USA). The cells in early stages
of apoptosis were Annexin V positive and PI negative, whereas the cells in the late
stages of apoptosis were both Annexin V and PI positive.
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4.2.3.4 Mitochondrial transmembrane potential (ΔΨm) assessment
The electrical potential difference across inner membrane (ΔΨm) was monitored
using the ΔΨm-specific fluorescent probe JC-1 (Beyotime Institute of Biotechnology,
Shanghai, China) [83]. The ΔΨm-specific fluorescent probe JC-1 exists as a monomer
with an emission at 530 nm (green fluorescence) at low membrane potential but forms
J-aggregates with an emission at 590 nm (red fluorescence) at higher potentials. A549
cells were treated with LZ-101 for 24 h. Cells were harvested and incubated with JC-1
for 30 min at 37 °C in the dark, then resuspended in washing buffer and relative
fluorescence intensities were monitored using flow cytometry (FACSCalibur, Becton
Dickinson, USA) with settings of FL1 (green) at 530 nm and FL2 (red) 585 nm.
4.2.3.5 Preparation of whole cell lysates and cytosolic and nuclear extracts
A549 cells were treated with LZ-101 at indicated concentrations for 24 h. The whole
cell lysates was prepared as described [84]. Nuclear and cytosolic protein extracts were
prepared using a Nuclear/Cytosol Fractionation Kit (BioVision, Mountain View, CA)
according to the manufacturer’s protocol. The cytosolic and nuclear fractions were
reserved for immunoblot analysis. Final detection was performed with Western blots.
4.2.3.6 Mitochondrial fractionation
Mitochondrial fractionation kit (KeyGen Biotech, China) was used to get
mitochondrial according to the following protocol. The cells were treated with different
concentrations of LZ-101 for 24 h and 3.5 ×107 cells were incubated with 1 mL ice-
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cold mitochondrial lyses buffer, then suspended and ground the cells with tight pestle
on ice. The homogenate was subjected to centrifugation at 800 g for 5 min at 4 °C to
remove nuclei and unbroken cells, and then added 0.5 mL supernatant to the 0.5 mL
Medium Buffer in the new 1.5 mL tube gently. After centrifugation at 15,000 g for 10
min at 4 °C, the supernatant was carefully removed and collected as the cytosolic
fraction and the remaining mitochondrial pellet was resuspended in the mitochondrial
extraction buffer.
4.2.3.7 Western blot analysis
The whole cell lysates, cytosolic extracts, nuclear extracts and mitochondrial
extracts were prepared as described above. Western blot analysis was carried out as
described previously [85]. Protein samples were separated by 10% SDS-PAGE and
transferred onto nitrocellulose membranes. The membranes were incubated with 1%
BSA at 37℃ for 1 h and then indicated antibodies overnight at 4℃, followed by
IRDye800 conjugated secondary antibody for 1 h at 37℃. Immunoreactive protein was
detected with an Odyssey Scanning System (LI-COR Inc., Lincoln, Nebraska).
4.2.3.8 Immunoﬂuorescence microscopy
For confocal imaging of fixed cells, A549 cells were used. After the appropriate
treatment, cells were ﬁxed with 4% paraformaldehyde in PBS, permeabilized with 0.5%
Triton X-100, and blocked with 3% BSA for 1 h. Samples was incubated with primary
antibodies (diluted 1:100) overnight at 4℃. After washed, Alexa Fluor 488 donkey antirabbit IgG, Alexa Fluor 594 donkey anti-rabbit IgG were used as secondary antibodies
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(Invitrogen, CA, USA). Samples were observed and captured with a confocal laser
scanning microscope (Olympus Corp., Tokyo, Japan).
4.2.3.9 Cell transfection
GFP-LC3, mCherry-GFP-LC3 plasmid (Addgene, MA, USA), the siRNA targeting
human FOXO3a, human ATG5, human ATG7 or control siRNA and the shRNA
targeting human Bax or control shRNA with scrambled sequence were transfected using
Lipofectamine 2000™ reagent (Invitrogen, CA, USA) according to the manufacturer’s
instructions.
4.2.3.10 Luciferase assay
A549 cells were seeded in 6-well plate, cultured for 24 h, and then transfected with
1 μg pGMFOXO-Lu (Genomeditech, Shanghai, China) and 0.05 μg pRL-TK Renilla
(Beyotime, Nantong, China) with 10 μL Lipofectamine 2000 and incubated for 24 h at
37℃ with LZ-101. Cells were lysed with Promega passive lysis buffer and assayed by
using Promega dual luciferase (Firefly luciferase/Renilla luciferase) kit. Luciferase
intensity was detected with a Luminoskan Ascent (Thermo Fisher Scientific Inc.
Finland).
4.2.4 In-vivo Study
4.2.4.1 Antitumor effects in nude mice
Male BALB/c nude mice, 35–40 days old and with weight ranging from 18-22 g,
were supplied by Shanghai Laboratory Animal Limited Company. The mice were
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maintained in a pathogen-free environment (23 ± 2℃ and 55 ± 5% humidity) on a 12
h light-12 h dark cycle with food and water supplied ad libitum throughout the
experimental period. Mice were subcutaneously inoculated with 1×106 A549 cells/
nude mice. After 12-14 days, tumor sizes were determined using micrometer calipers,
then nude mice with similar tumor volume (eliminate mice with tumors that are too
large or too small) were randomly divided into four groups (6 /group): one saline tumor
control group; (i.v.) 5-fluorouracil 30 mg/ml/2 days group; (i.v.) LZ-101 10 mg/kg/2
days group; (i.v.) LZ-101 20 mg/ml/2 days group. At the end of 3 weeks, the mice were
sacrificed, and the tumor xenografts were removed and measured. Tumor volume (TV)
was calculated using the following formula: TV (mm3) = d2×D/2, where d and D are
the shortest and the longest diameters, respectively. This study was approved in SPF
Animal Laboratory of China Pharmaceutical University.
4.2.4.2 TUNEL assay
Apoptosis induction in the tissue specimen was analyzed by TUNEL assay. It was
performed as per instructions given in situ cell death kit. The slides were photographed
with a confocal laser scanning microscope (Fluoview FV1000, Olympus, Tokyo, Japan).
4.2.4.3 Immunohistochemistry
The expression of FOXO3a, Bim, Bcl-2, Bax of the tissues of control and LZ-101
(20 mg/kg) treated groups was assessed by SP immunohistochemical method using a
rabbit-anti-human monoclonal antibody and an Ultra-Sensitive SP kit (kit 9710
MAIXIN, Fuzhou, Fujian). Tissue sections (4 mm thick) were placed onto treated slides
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(Vectabond, Vector Laboratories, Burlingame, CA). Sections were heat fixed,
deparaffinized and rehydrated through graded alcohols (100%, 95%, 85%, 75%) to
distilled water. Tissue sections were boiled in citrate buffer at high temperature for
antigen retrieval, and treated with 3% hydrogen peroxide to block endogenous
peroxidase activity. The slides were incubated with a protein-blocking agent (kit 9710
MAIXIN, Fuzhou, Fujian) prior to the application of the primary antibody, and then
incubated with the primary antibody at 4℃ overnight. The tissues were then incubated
with the secondary biotinylated anti-species antibody and labeled using a modification
of the avidin-biotin complex immunoperoxidase staining procedure according to the
UltraSensitive SP kit manual. Counterstaining was done with Harris hematoxylin. All
reagents were supplied by MaixinBio Co. (Fuzhou, China).
4.3 Results & Discussion
4.3.1 LZ-101 inhibited cell viability in human non-small-cell lung cancer cells
To evaluate the inhibitory effect of LZ-101 on human non-small-cell lung cancer
cells including A549, H1299 and H460 cells, we investigated its effect on cell viability
at different concentrations with varying lengths (12, 24 or 48 h) of treatment. The IC50
(the concentration of drug inhibiting 50% of cells) values for A549 cells were 13.95 ±
2.24, 8.61 ± 0.75 and 4.28 ± 0.42 μM, respectively, after 12, 24 and 48 h treatment.
Whereas, the IC50 values for H1299 were 44.47 ± 6.54, 18.47 ± 0.86 and 6.75± 0.58
μM, respectively, after 12, 24 and 48 h treatment. In H460 cells, the IC50 values were
22.49 ± 4.52, 13.15 ± 1.02 and 6.80 ± 0.72 μM, respectively, after 12, 24 and 48 h
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treatment (Figure 4.5). As shown in Figure 4.6, treatment with 5, 10 and 15 μM LZ-101
for 24 h significantly inhibited the surviving of A549, H1299 and H460 cells with A549
cells being the most sensitive to LZ101. Therefore, A549 cell line was chosen for
further experiments with 5, 10 and 15 μM of LZ-101 treatment for 24 h.

Figure 4.5 MTT assay was used to detect cell viability after treatment of different
concentrations of LZ-101 for 12 h, 24 h and 48 h in A549, H1299 and H460.

Figure 4.6 Cell viability was detected after treatment of 5, 10 and 15 μM LZ-101 for 24 h in
A549, H1299 and H460 cells.

To explore the mechanism of LZ-101 inhibiting A549, H1299 and H460 cells
survival, cells were also treated with a pan-caspase inhibitor, Q-VD-OPh, during LZ101 treatment. Survival inhibition of LZ-101 was significantly inhibited in A549,
H1299 and H460 cells, when caspase activity was inhibited by Q-VD-OPh (Figure 4.7).
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This suggests that LZ-101 inhibited the survival of human non-small cell lung cancer
cells by triggering apoptosis.

Figure 4.7 Cell viability was detected after treatment of 20 μM Q-VD-OPh or 15 μM LZ-101
for 24 h in A549, H1299 and H460 cells.

4.3.2 LZ-101 induced mitochondrial apoptosis in A549 cells
To detect the apoptosis induced by LZ-101 in A549 cells, DAPI staining assay and
Annexin V/PI staining were used with rotenone as positive control. In DAPI staining
assay, control cells emitted blue fluorescence with consistent nucleus intensity and
showed typical homogeneous distribution of chromatin in nucleus. After LZ-101
treatment, cells presented morphological features of bright apoptotic bodies and nuclear
condensation (Figure 4.8 arrows). These features appeared more frequently with
increasing concentrations of LZ-101.

Figure 4.8 DAPI staining was used to detect the apoptosis. Scale bars, 50 µm.
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To further confirm the apoptosis induced by LZ-101, Annexin V/PI staining assay
was used. As shown in Figure 4.9, increased apoptotic was detected after LZ-101 or
rotenone treatment for 24 h. The percentage of apoptotic cells increased from 6.07% ±
1.62% to 14.92% ± 4.32%, 22.07% ± 4.32%, and 43.62% ± 7.83%, respectively.
Furthermore, the apoptosis related proteins such as Bcl-2, Bax, caspase-9 and PARP
were investigated by Western blots. After treatment with LZ-101 for 24 h, the apoptotic
protein Bax expression increased while the anti-apoptotic protein Bcl-2 expression
decreased in a concentration-dependent manner (Figure 4.10). The ratio of Bax/Bcl-2
is crucial for the activation of the mitochondrial apoptotic pathway. The ratio of
Bax/Bcl-2 was increased by different concentrations of LZ-101 treatment. Besides,
Caspase-9 and PARP cleavage were activated significantly after LZ-101 treatment
(Figure 4.10). These data indicated that LZ-101 induced apoptosis in A549 cells.

Figure 4.9 Induction of apoptosis were measured by Annexin-V/PI double-staining assay.
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Figure 4.10 The levels of Bax, Bcl-2, caspase-9 and PARP were assessed by Western blot. Ratio
of Bax/Bcl-2 expression using densitometric analysis.

In order to elucidate the mechanism of LZ-101-induced apoptosis in A549 cells, we
investigated the effect of LZ-101 on mitochondrial function. Changes in mitochondrial
functions are essential for mitochondrial apoptotic pathway. In early apoptosis stage,
the change of mitochondrial membrane potential (ΔΨm) is a marker for mitochondrial
dysfunction. Accordingly, we used a fluorogenic probe JC-1 staining cells to detect the
change of ΔΨm after LZ-101 treatment. Flow cytometric analysis revealed that A549
cells became more susceptible to mitochondrial membrane depolarization after LZ-101
treatment (Figure 4.11). We observed almost 50% decrease in ΔΨm with 15 μM LZ-101,
compared with the control group. Multidomain proapoptotic proteins like Bax and Bak
play pivotal roles in the release of apoptogenic proteins, such as cytochrome c and AIF,
from the mitochondria into the cytosol in response to apoptotic stimuli [84]. To study
the involvement of Bax in LZ-101-induced apoptosis, we used Bax shRNA to diminish
the expression of Bax. As shown in Figure 4.12, cytochrome c and AIF were released
from mitochondria upon LZ-101 treatment whereas their release was almost completely
blocked in Bax knockdown cells and β-actin levels of all the fractions were similar.
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Taken together, our findings suggested that LZ-101 induced apoptosis was mediated by
mitochondrial dysfunction in A549 cells.

Figure 4.11 The change of ΔΨm as detected by flow cytometry using JC-1 staining.

Figure 4.12 The release of Cyt c and AIF from mitochondria into cytoplasm was measured by
Western blot assay after knockdown of Bax.

4.3.3 The up-regulation of FOXO3a expression was involved in LZ-101 induced
apoptosis of mitochondrial
When cells receive intrinsic apoptosis signals, the pro-apoptotic BH3-only proteins,
such as Bim, Bad, Noxa and Puma, will be activated. These proteins not only inhibit
the activity of anti-apoptotic protein (Bcl-2, Bcl-xL and Mcl-1), but also activate the
pro-apoptotic protein (Bax and Bak), which form an oligomer and subsequently punch
pores in the outer mitochondrial membrane, eventually, leading to permeabilization of
mitochondrial outer membrane [67]. As mentioned before, although pro-apoptotic
BH3-only protein Bim plays a crucial role in apoptosis, it could be regulated by
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FOXO3a at transcriptional level. Therefore, we investigated the effect of LZ-101 on
this signalling pathway. Western blots analysis showed that Bim increased in A549 cells
after LZ-101 treatment for 24 h (Figure 4.13). This result confirms that FOXO3a
regulated the transcription of Bim. Moreover, we found that LZ-101 up-regulated
FOXO3a protein expression in A549 cells (Figure 4.13). The change of mRNA level of
Bim, tested by Real-time PCR, was consistent with that of the protein levels (Figure
4.14). Furthermore, Luciferase reporter gene assay suggested that LZ-101 increased
transcriptional activity of FOXO3a in a concentration-dependent manner (Figure 4.15).
LZ-101 also promoted FOXO3a to translocate into the nucleus (Figure 4.16). Therefore,
LZ-101 up-regulates the expression of FOXO3a and promotes the transcription of Bim.

Figure 4.13 The levels of FOXO3a and Bim were assessed by Western blot after 5, 10 and 15
μM LZ-101 treatment for 24 h.

Figure 4.14 Bim mRNA was measured by real-time PCR following treatment with 5, 10 and
15 μM LZ-101 for 24 h in A549 cells.
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Figure 4.15 The transcriptional activities of FOXO3a in A549 cells co-transfected with
pGMFOXO-Lu and pRL-TK Renilla with LZ-101.

Figure 4.16 Immunoﬂuorescence staining of FOXO3a in A549 cells was carried out to test the
effect of LZ-101 on FOXO3a protein nuclear translocation.

To further explore the mechanism of LZ-101-induced apoptosis and determine the
roles of FOXO3a activation in this process, we detected the influence of LZ-101 on
Bax and Bcl-2 expression after FOXO3a siRNA transfection. Western blot results
showed that the protein level of Bax and Bcl-2 were notably regulated by LZ-101.
However, these effects of LZ-101 were obviously reversed by the knockdown of
FOXO3a (Figure 4.17). Remarkably, the ratio of Bax/Bcl-2 increased by LZ-101 was
also reversed. Moreover, Flow cytometry analysis demonstrated that the percentage of
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apoptotic cells in LZ-101 group transfected with FOXO3a siRNA reduced from 50.47%
± 8.59% to 19.44% ± 3.63%, compared with LZ-101 group without transfection with
FOXO3a siRNA (Figure 4.18). The decrease of mitochondrial potential was inhibited
in LZ-101 group transfected with FOXO3a siRNA compared with LZ-101 group
(Figure 4.19). In conclusion, the up-regulation of FOXO3a expression was involved in
the induction of mitochondrial apoptosis by LZ-101.

Figure 4.17 FOXO3a, Bim, Bax and Bcl-2 were detected by Western blot.

Figure 4.18 Annexin-V/PI staining assay were measured after knockdown of FOXO3a.
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Figure 4.19 The change of ΔΨm were measured by flow cytometry after knockdown of
FOXO3a.

4.3.4 LZ-101 increased the stability of FOXO3a in a proteasome-independent
manner
To further investigate the molecular mechanism by which LZ-101 up-regulates
FOXO3a expression, de novo protein synthesis inhibitor cycloheximide (CHX) and
proteasome inhibitor MG132 were used, respectively. After treatment of CHX,
FOXO3a was more stable in A549 cells treated by LZ-101 compared with A549 cells
treated by DMSO (Figure 4.20), indicating that LZ-101 interfered with FOXO3a
degradation. In support of this observation, when MG132 (20 μM) was added to A549
cells, increased FOXO3a levels were observed, whereas LZ-101 unexpectedly further
increased FOXO3a levels in A549 cells treated with MG132 (Figure 4.21). Further
detection of apoptosis levels showed that LZ-101 significantly increased apoptosis
induced by MG132 (Figure 4.22). These results suggested that LZ-101 interfered with
FOXO3a degradation in a proteasome-independent manner.

77

Figure 4.20 Degradation dynamics of FOXO3a following a time course CHX treatment in
A549 cells treated with 15 μM LZ-101.

Figure 4.21 FOXO3a proteins were stabilized in the presence of MG132 (20 μM) in A549 cells
treated with 15 μM LZ-101.

Figure 4.22 Annexin-V/PI staining assay measured by flow cytometry in the presence of
MG132 (20 μM) in A549 cells treated with 15 μM LZ-101.

In addition to proteasome degradation of proteins in cells, the autophagic lysosomal
pathway may also be involved in protein degradation. To confirm this hypothesis we
detected the co-localization of FOXO3a and LAMP1 in A549 cells. As shown in Figure
4.23, LZ-101 indeed inhibited the co-localization of FOXO3a and LAMP1. To further
confirm FOXO3a is degraded by the autophagic lysosomal pathway, an
autophagolysosome inhibitor, bafilomycin A1, was used. After treatment with
bafilomycin A1, FOXO3a degradation was inhibited, combination of bafilomycin A1
with LZ-101 could not further inhibit FOXO3a degradation (Figure 4.24). These results
suggested that LZ-101 increased the stability of FOXO3a through the autophagic
lysosome pathway rather than the ubiquitin proteasome pathway.
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Figure 4.23 Confocal microscopy of A549 cells treated with 15 μM LZ-101 or 100 nM
rapamycin, immunostained for FOXO3a (green) and LAMP-1 (red).

Figure 4.24 FOXO3a was detected after 15 μM LZ-101 and 30 nM bafilomycin A1 treatment.

4.3.5 LZ-101 blocked autophagy flux in A549 cells
In Figures 4.23, 100 nM rapamycin remarkably increased the co-localization of
FOXO3a and LAMP1 in A549 cellls. This is consistent with the study that FOXO3a is
an autophagy substrate [86]. To further investigate the molecular mechanism by which
LZ-101 increased the stability of FOXO3a, we investigated the effect of LZ-101 on
autophagy. LC3-I and LC3-II are both produced post-translationally, but LC3-I is
cytosolic and LC3-II, the hallmarks of autophagy, is membrane bound and forms the
autophagosome [87]. Treatment with 15 μM LZ-101 increased GFP-LC3 puncta
accumulation (Figure 4.25). Then, we assessed LC3 in the cell lysates by immunoblot
analysis. We found that LC-II protein levels gradually increased following treatment
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with LZ-101 in A549 cells (Figure 4.26), indicateing that LZ-101 increased
autophagosome formation in A549 cells.

Figure 4.25 Induction of GFP+ dots in A549 cells expressing GFP-LC3 treated with 15 μM LZ101. Images of individual cells and quantified of GFP-LC3+ cells. Scale bars, 10 µm

Figure 4.26 p62 and LC3 were detected by Western blot in A549 cells treated with 15 μM LZ101.

Since enhanced autophagosome accumulation could be caused either by promoted
autophagosome formation or by suppressed autophagosome degradation, we
determined whether a complete autophagic flux occurred after LZ-101 treatment. As
shown in Figure 4.26, the degradation of p62 was significantly suppressed in A549 cells
with LZ-101 treatment. To further assess the status of autophagic flux, we used the
mCherry-GFP-LC3 construct. As the more stable of mCherry in acidic conditions
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compared with GFP, autophagic flux can be determined by the appearance of more
GFP- mCherry+ (red) puncta. After treatment with LZ-101, large-sized GFP+ mCherry+
(yellow) puncta were observed, while the yellow puncta did not change significantly
after bafilomycin A1 treatment (Figure 4.27). These results indicated that LZ-101
blocked autophagy flux in A549 cells by inhibiting autophagosome degradation.

Figure 4.27 A549 cells expressing mCherry-GFP-LC3 were observed under a confocal
microscopy after 15 μM LZ-101 and 30 nM bafilomycin A1 treatment.

4.3.6 Inhibition of autophagosome formation abolished the induction of apoptosis
by LZ-101
To investigate the role of autophagy in the induction of apoptosis by LZ-101, we
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blocked the formation of autophagosomes with 3-MA. After treatment with 3-MA, the
effect of LZ-101 to stabilize FOXO3a abolished (Figure 4.28). In addition, the effect of
LZ-101 induced apoptosis was similarly abolished after treatment with 3-MA (Figure
4.29). In the process of autophagy, ATG5 and ATG7 are required for the formation of
the autophagosome (need references here to support this statement). As shown in Figure
4.30, we silenced the expression of ATG5 or ATG7 through transfecting siRNA. The
induction of apoptosis was abolished after diminishing the expression of ATG5 or ATG7
in LZ-101-treated A549 cells. Thus, blocking the formation of autophagosome
abolished LZ-101 induced apoptosis of A549 cells.

Figure 4.28 FOXO3a was detected by Western blot in the presence of 3-MA (4 mM) in A549
cells treated 15 μM LZ-101.

Figure 4.29 Annexin-V/PI staining assay by flow cytometry in the presence of 3-MA (4 mM)
in A549 cells treated with 15 μM LZ-101.
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Figure 4.30 Annexin-V/PI staining assay by flow cytometry in A549 cells treated with 15 μM
LZ-101 and transfected ATG5 or ATG7 siRNA.

4.3.7 LZ-101 exerted antitumor effect with low toxicity in A549 inoculated
xenograft mice
The xenograft mice transplanted with A549 cells were used to evaluate the antitumor
effect of LZ-101 in vivo. The tumor volume of mice with LZ-101 treatment was smaller
than that of mice in control group but larger than that of mice in 5-fluorouracil-treated
group at the same measurement day (Figure 4.31). Moreover, the tumor weight of LZ101-treated mice was significantly smaller than that of the control group (Figure 4.32).
Accordingly, the inhibitory rates of 5-fluorouracil, 10 mg/kg and 20 mg/kg LZ-101
groups were 68.05%, 40.86% and 55.62%, respectively (Table 4.1). The TUNEL assay
was performed to detect apoptotic cells in tumor tissues. The results indicated that DNA
damage in tumor tissues was induced by LZ-101. In addition, immunohistochemical
analysis showed that p-Akt and Bcl-2 expression were decreased while FOXO3a, Bim
and Bax expression were increased after LZ-101 treatment (Figure 4.33).
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Figure 4.31 Tumor volumes of control, 5-fluorouracil, LZ-101 treatment groups were
measured and calculated every 3 days.

Figure 4.32 Weight of tumor in control, 5-fluorouracil, LZ-101 treatment groups.

Table 4.1 Inhibitory activity of LZ-101 against A549 xenograft tumor.

Groups

Dose (mg/kg)

Inhibitory rate (%)

5-Fluorouracil

30

68.05**

10

40.86**

20

55.62**

LZ-101

**P

< 0.01 versus control group.
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Figure 4.33 DNA damage and FOXO3a, Bim Bcl-2, Bax expression detected by TUNEL assay
and immunohistochemistry in tumor xenograft tissues.

Furthermore, we monitored the toxicity of LZ-101 during the entire in vivo
experiment. LZ-101 treatment (21 days) did not cause any physical abnormalities.
Hematological parameters showed that there were no notable changes in the analysed
parameters in the experimental animals, as listed in Table 4.2 with the standard ranges
for mice. Besides, there was no significant difference in the average body weight of
LZ-101-treated mice compared with that of the control mice (Figure 4.34). H&E
staining (Figure 4.35) showed no morphological changes in the organs of mice with
LZ-101 treatment. Taken together, our results suggested that LZ-101 inhibited tumor
growth via FOXO3a activation in xenograft mice bearing A549 tumor with low toxicity
in vivo.
Table 4.2 Hematology profile in non-tumor bearing athymic nude mice administered with
normal saline. Two mice per group were used. Standard ranges were obtained in house from
100 normal BALB/c mice of 8-12 weeks age.
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Hematological parameters

Control

10 mg/kg

20 mg/kg

Standard

White blood cells (×103 μl)

4.71/4.42

4.90/4.95

5.87/5.74

4.5-9.1

Red blood cells (× 106/μl)

9.76/10.70

10.51/9.84

10.25/9.30

7.51-16.1

Hemoglobin (g/dL)

14.5/13.0

15.2/14.2

14.9/13.9

12.8-16.1

Hematocrit (%)

44.8/41.8

47.9/45.3

46.9/44.7

34-50

Lymphocytes (%)

67.2/78.8

50.4/61.4

55.4/63.1

49-82

Monocytes (%)

2.64/4.24

4.54/5.24

3.14/4.64

2-8

Eosinophils (%)

0.24/0.34

0.04/0.74

0.54/0.64

0-3

Basophils (%)

0.24/0.74

0.34/0.34

0.54/0.24

0-3

Platelet (×103 μl)

507/410

560/483

526/744

115-1037

Mean corpuscular volume (fL)

45.9/45.8

45.6/46.0

45.8/48.1

41-60

Mean corpuscular hemoglobin (pg)

14.9/14.3

14.5/14.4

14.5/14.9

13-19

Figure 4.34 Nude mice weight was recorded every three days.
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Figure 4.35 H&E stained main organs of mice from treated and control sets to evaluate the
toxicity of LZ-101.

4.4 Conclusion
In summary, LZ-101 displayed strong antitumor activity both in vitro and in vivo
based on the mitochondrial apoptosis induced by up-regulation of Bim through
stabilizing FOXO3a in autophagic lysosomal dependent manner (Figure 4.36).
Moreover, how FOXO3a escapes from autophagosomes to induce transcription remains
unknown. Studies have shown that inhibition of autophagy in different means promoted
the transcription of FOXO3a. It was suggested that inhibition of autophagy induced
FOXO3a activation was not a specific function of LZ-101. Therefore, the relationship
between autophagy and FOXO3a activation needs further study and is underway in our
laboratories. In conclusion, this study indicated that LZ-101 could be a potential
effective agent with low toxicity for human non-small-cell lung carcinoma.
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Figure 4.36 The possible mechanism of LZ-101 induced apoptosis in NSCLC.
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CHAPTER V.
PERTURBING THE UNIQUE ENERGY METABOLISM IN CANCER CELLS,
A REVISIT OF THE WARBURG EFFECTS
5.1 Background
5.1.1 Development of breast cancer treatment
Breast cancer is the most common cancer in women worldwide (second most
common cancer overall). In 2017, the number of new cases and deaths from breast
cancer reached 252,710 and 40,610, respectively [88]. In China, breast cancer is the
most common cancer among female, with the incidence 17.07% and 278,800 new cases,
ranking fifth in the causes of tumor death after cancers of lung, gastric, liver and
colorectum [89]. Depending on the type and degree of advancement, breast cancer is
treated with surgery and then possibly chemotherapy and/or radiation therapy. Among
all the breast cancer cases, 15% are triple-negative breast cancers (TNBCs), which lack
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2) and have a very aggressive disease course [90]. 10%
to 20% of women who have TNBC subtype breast cancers usually have shorter survival
due to high malignancy, high recurrence rate and high transferability [91]. Compared
with the well-defined behavior of breast cancer, the molecular mechanism of breast
cancer initiation and progression remains poorly understood. The lack of approved
targeted therapies and effective chemotherapy with low toxicity for TNBC remains a
major hindrance for treatment and prompted us to identify novel targets.
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Fiugre 5.1 Global Maps Presenting the Most Common Type of Cancer Incidence in 2018 in
Each Country Among (A) Men and (B) Women[92].

5.1.2 Characteristics of glucose metabolism in cancer
Under aerobic conditions, normal cells process glucose, first to pyruvate via
glycolysis in the cytosol and thereafter to carbon dioxide in the mitochondria; under
anaerobic conditions, glycolysis is favored and relatively little pyruvate is dispatched
to the oxygen-consuming mitochondria. However, cancer cells have a unique energy
metabolism manner, which was first proposed by Warburg almost a century ago: even
in the presence of oxygen, cancer cells can reprogram their glucose metabolism, and
thus their energy production, by limiting their energy metabolism largely to glycolysis,
leading to a state that has been termed ‘‘aerobic glycolysis’’ [93]. The shift in energy
production from mitochondrial oxidative phosphorylation (OXPHOS) to aerobic
glycolysis is a hallmark of cancer development [94]. Aerobic glycolysis not only
supports rapid growth, but also makes the cancer cells less dependent on oxygen
availability and generates a suitable micro-environment for cancer progress [95].
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Studies of the metabolic changes in cancers proide rationale for and insight about cancer
therapy.

Some rate-limiting enzymes of glycolysis, such as hexokinase (HK) and

pyruvate kinase (PK) have, in addition to ensuring glycolytic reactions, other biological
functions such as regulation of transcription and induction of apoptosis [96, 97]. Some
inhibitors or regulators of glycolytic enzymes have been developed to extract cancer
cells’ “sweet tooth” [98]. The recent approval of the first tumor metabolism regulating
drug, Enasidenib, by FDA served as a new gateway to cancer therapy. Inhibition of
glycolysis is attracting increasing attention as a novel therapeutic focus in cancer
managements.

Fiugre 5.2 The unique glucose metabolism in cancer cells [99].

5.1.3 Functions of HK2 in cancer cells
The high glycolytic rate is closely connected with the greatly increased expression
of hexokinase II (HK II), and its binding to the mitochondria through the voltagedependent anionic channel (VDAC) in malignant cells [100]. HK II mediates the first
rate-controlling step of glycolysis, phosphorylating glucose to glucose-6-phosphate.
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VDAC is a mitochondrial porin located in the outer mitochondrial membrane (OMM)
and is responsible for the exchange of metabolites and ions between mitochondria and
other cellular compartments [101]. It has been demonstrated that binding of HK II to
VDAC inhibits apoptosis as a result of alterations in the permeability of OMM [102].
It was also reported that the increased binding of HK II to VDAC was associated with
drug resistance of cancer cells to chemotherapeutic agents [86]. In malignant tumors,
the level of HK II expression was 10 fold higher than normal tissues [103]. Stable
binding of HK II to mitochondria promotes aerobic glycolysis, but impairs
mitochondrial respiration [104]. HKII binds to VDAC through both its N-terminal
membrane binding domain and its putative BH4 domain, which is proposed to compete
with the binding of VDAC to Bcl-xL (an anti-apoptotic member of the BCL-2 family
proteins) [105]. Thus, HKII binding displaces Bcl-xL from VDAC and thereby
facilitates its direct interaction with proapoptotic BCL-2 family members, such as Bax
and its homolog Bak, and protects against OMM permeabilization. Alternatively, if HK
II was detached, it may prevent Bcl-xL from binding to Bax, resulting in the release of
cytochrome c and other apoptosis enhancing proteins.
AKT is an oncogene protein kinase that controls various cellular functions and can
exert antiapoptotic effects [106]. It was reported that AKT could phosphorylate HKII
at threonine 473 directly, resulting in the increased binding of HKII with VDAC and
the observed anti-apoptotic effects [107]. In addition to the direct action on HKII, AKT
could influence the binding of HKII with VDAC through its downsteam negative
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regulating factor GSK-3β. When AKT is inhibited, GSK-3β is dephosphorylated and
activated. A large proportion of GSK-3β is found in the cytosol, but pools are also found
in the nucleus and mitochondria. Many studies demonstrated that GSK-3β was
implicated in inducing mitochondrial dysfunction. DNA damage induced the
interaction between GSK-3β and p53 at the mitochondria, whereas inhibition of GSK3β blocked caspase activation and suppress apoptosis [108]. GSK-3β phosphorylate
VDAC on Thr51 region, which is highly conserved in mitochondrial porins and is in
close proximity to Glu72, a residue critical to the binding of VDAC with HK II [109].

Figure 5.3 Proposed mechanism of HKII-mediated protection against outer mitochondrial
membrane (OMM) permeabilization [110].

5.1.4 A new synthesized flavonoid GL-V9 with potential anticancer activity
GL-V9 (5-hydroxy-8-methoxy-7-(4-(pyrrolidin-1-yl)butoxy)-4H-chromen-4-one)
is a newly synthesized flavonoid derivatived from natural product wogonin, which has
been reported to possess anti-cancer properties in previous studies. GL-V9 inhibits
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tumor invasion and metastasis via downregulating the expression and activity of matrix
metalloproteinase-2/9 in MDA-MB-231 and MCF-7 cell lines in vitro [111]. It has also
been observed that GL-V9 triggers mitochondria mediated apoptosis and reverses
hypoxia–drug resistance in human hepatocellular carcinoma [112, 113].

Figure 5.4 Chemical structure of GL-V9

5.2 Materials and Methods
5.2.1 Reagents
GL-V9 (5-hydroxy-8-methoxy-7-(4-(pyrrolidin-1-yl) butoxy)-4H-chromen-4-one,
C24H27NO5, MW 409.47, purity>99%) and wogonin (5,7-Dihydroxy-8-methoxy-2phenyl-4H-chromen-4-one, C16H12O5, MW 284.27, purity>99%) were dissolved in
dimethyl sulfoxide (Sigma–Aldrich, St. Louis, MO, USA) to 100 mM as a stock
solution, stored at -20 °C, and diluted with medium before each experiment. The final
DMSO concentration did not exceed 0.1% throughout the study. LiCl was purchased
from Sigma-Aldrich and dissolved in distilled water to make a 100 mM stock solution.
Human recombinant IGF-1 was purchased from Merck Millipore (αIGF-1; 10 µg/mL;
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Millipore, Ireland). MK-2206 dihydrochloride (MK) was purchased from Santa Cruz
Biotechnology Inc (Santa Cruz, CA) and dissolved in DMSO.
5.2.2 Synthetic route of GL-V9
GL-V9 was synthesized from wogonin (5,7-dihydroxy -8-methoxy-2-phenyl-4H-1benzopyran-4-one, C16H12O5, MW 284.26). Synthesis of the GL-V9 was initiated from
wogonin, which was react with 1,4-dibromobutane and potassium carbonate by
refluxing in acetone in the presence of K2CO3 about 7 hours to give compound 3 (7-(4bromobutoxy)-5-hydroxy-8-methoxy-2-phenyl-4H-chromen-4-one) . Then the pyrrole
ring was introduced on the bromine of compound 3 by refluxing with tetrahydropyrrole
in acetonitrile about 4~5 hours to obtain GL-V9.

Figure 5.5 The synthetic route of GL-V9. (1) Molecular structure of GL-V9, (2) Molecular
structure of wogonin, (3) halogenated hydrocarbons.

5.2.3 In-vitro Study
5.2.3.1 Cell Viability Assays
Cell

viability

was

measured

using

3-[4,5-dimethylthiazol-2-yl]-2,5-

diphenyltetrazolium bromide (the MTT assay). Cells (1×104) were treated with GL-V9
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for 36 h at various concentrations (0~80 μM). Absorbance of the resulting formazan
was measured spectrophotometrically at 570 nm using a Universal Microplate Reader
EL800 (BIO-TEK instruments, Inc., Vermont, MA).
5.2.3.2 Lactic Acid Production
The generation of lactic acid in cell culture media treated with GL-V9 was assayed
using the Lactic Acid Detection kit (KeyGen, Nanjing, China) following the
manufacturer’s instructions. The assay was monitored spectrophotometrically at 570
nm using the Thermo Scientific Varioskan Flash spectral scanning multimode reader
(Thermo, Waltham, MA).
5.2.3.3 ATP Assessment
Cellular ATP concentrations were measured with the ATP Bioluminescent Somatic
Cell Assay Kit from Sigma. After cells were incubated with GL-V9 for 36 h, cultured
cells were lysed in an ice-cold ATP releasing buffer. Using an ATP standard provided
by Sigma, ATP concentrations were then determined with the kit, and normalized to
protein concentrations. Aliquots of 100 μL were transferred to white 96-well assay
plates. Following the addition of 100 μL luciferin and luciferase, luminescence was
monitored on a luminometer Orion II (Berthold DS, Bleichstr, Pforzheim, Germany).
5.2.3.4 Glucose uptake assay
Glucose was assayed using the Amplex Red Glucose Assay Kit (Invitrogen, Eugene,
OR). After treatment, media was collected and diluted 1:4,000 with water. The amount
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of glucose was detected using a fluorometer (Thermo, Waltham, MA) at Ex./Em. = 530
nm / 590 nm according to the instructions of the assay kit. Glucose uptake was
determined by subtracting the amount of glucose in each sample from the total amount
of glucose in the media (without cells).
5.2.3.5 Measurements of oxygen consumption
Cells were seeded at a density of 0.2 × 106 cells per well in a 96-well BD Oxygen
Biosensor System plate (BD Biosciences, San Jose, CA, USA), and culture media was
added until a final volume of 200 μL per well was attained. After drug treatments, the
plates were maintained at 37 °C in a humidified incubator with 5% CO2. Plates were
scanned in a temperature-controlled (37 °C) plate reader (Thermo, Waltham, MA) with
an excitation wavelength of 485 nm and an emission wavelength of 630 nm at
predetermined times for a total of 72 h. The fluorescence traces in each well were
normalized according to the signal in the air-saturated buffer. Slopes of fluorescence
signal were calculated in the dynamic range of measurements to compare the
respiratory rates of samples. Normalized relative fluorescence unit represents oxygen
consumption.
5.2.3.6 Mitochondrial Membrane Potential Determination
Following treatment, cells were harvested and resuspended with ice-cold PBS (2000
rpm × 5 min). Quantitative changes of mitochondrial membrane potential (MMP) at the
early stage of cell apoptosis were measured by the Mitochondrial membrane potential
Detection kit (KeyGen, Nanjing, China) with the lipophilic cation 5,5',6,6'-tetrachloro97

1,1',3,3'-tetraethylbenzimidazolcarbocyanine

iodide

(JC-1)

and

detected

by

FACSCalibur flow cytometry (Becton Dickinson, San Jose, CA) .
5.2.3.7 ROS Measurement
ROS level was assessed using the fluorescent dye 2’7’-dichlorfluorescein-diacetate
(DCFH-DA, Beyotime Institute of BioTechnology, Haimen, China) following the
methods reported by Wei et al [114].
5.2.3.8 Preparation of mitochondrial extracts
After incubation with GL-V9 for 36 h, the fractionation of the mitochondrial protein
was extracted with the Mitochondria/Cytosol Fractionation Kit (BioViso, VA, USA).
Briefly, 5 × 107 cells were collected by centrifugation at 600 × g for 5 min at 4 °C and
washed with ice-cold PBS. Cells were resuspended with 1 mL of 1 × Cytosol Extraction
Buffer Mix containing dithiothreitol and protease inhibitors and incubated on ice for 10
min. Then, cells were homogenized in an ice-cold grinder and the homogenate was
transferred to a 1.5 ml microcentrifuge tube and centrifuged at 700 × g for 10 min at
4 °C. The supernatant was transferred to a fresh 1.5 mL microcentrifuge tube and
centrifuged at 10 000 × g for 30 min at 4 °C. The supernatant was collected as cytosolic
fraction and the pellet was resuspended in 0.1 ml Mitochondrial Extraction Buffer Mix
containing DTT and protease inhibitors and then vortexed for 10 s and saved as
mitochondrial fraction.
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5.2.3.9 Immunoprecipitation
For co-immunoprecipitation of VDAC complexes, VDAC were immunocaptured
from mitochondrial extracts. Lysate of mitochondrial fraction (1 mL) containing 1.5 mg
total protein was incubated, respectively, with 1 mg VDAC antibody and 20 mL protein
A/G-conjugated beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight.
After four washes with TNES buffer, samples were centrifuged at 3000 × g for 2 min
and resuspended in 20 mL SDS-sample buffer (0.5 M Tris–HCl, pH6.8, 20% glycerol,
2% SDS, 5% 2-mercaptoethanol, 4% bromophenol blue). For western blot analysis, 10
ml samples were used. The immunocomplexes were analyzed by western blotting and
probed with antibody against anti-GSK3β or HKII antibody.
For co-immunoprecipitation of GSK3β complexes, GSK3β were immunocaptured
from mitochondrial extracts. The same experimental procedures were conducted as
described for VDAC complexes above. The immunocomplexes were analyzed by
western blotting and probed with antibody against VDAC or HKII antibody.
5.2.3.10 Statistical evaluation
Data are presented as mean ± S.D. from triplicate parallel experiments unless
otherwise indicated. Statistical analysis was performed using one-way ANOVA. Least
Significant Difference test and Tukey’s HSD test were used for the one-way ANOVA
analyses.
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5.2.4 In-vivo Study
5.2.4.1 In vivo tumor growth assay
Female athymic BALB/c nude mice (35-40 days old) with body weight ranging from
18 to 22 g were supplied by the Academy of Military Medical Sciences of the Chinese
People’s Liberation Army (Certificate No. SYXK-(Su)2016-0010). The animals were
kept at 22 ± 2 °C and 55-65% humidity in stainless steel cages under controlled lights
(12 h light/day) and were fed with standard laboratory food and water. Animal care was
conducted in accordance with the recommendations of the Guide for the Care and Use
of Laboratory Animals published by the National Institute of Health, USA. This
experiment was conducted in accordance with the guidelines issued by the State Food
and Drug Administration (SFDA of China).
Forty nude mice were inoculated subcutaneously with 1 × 107 MDA-MB-231 or
MCF-7 cells into the right axilla. After 12 days of growth, tumor sizes were determined
using micrometer calipers. Mice with similar tumor volumes (mice with tumors that
were too large or too small were eliminated) were randomly divided into the following
five groups (6 mice per group): saline control, GL-V9 (20 mg/kg, i.v., every 2 days ),
wogonin (6 mg/kg, i.v., every 2 days), and Taxol (8 mg/kg, i.v., twice a week). Tumor
sizes were measured every 3 days using micrometer calipers and tumor volume was
calculated using the following formula: TV (mm3) =d2 × D/2, where d and D were the
shortest and the longest diameter, respectively. Mice were sacrificed on day 21, and
tumor tissues were used for immunofluorescence and immunohistochemistry assays.
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5.2.4.2 Immunohistochemistry & Immunofluorescence for tumor tissue
The expressions of GSK3β, p-GSK3β, AKT, p-AKT in the tumor tissue were
assessed by the SP immunohistochemical method using a rabbit-antihuman monoclonal
antibody and an Ultra-Sensitive SP kit (kit 9710 MAIXIN, Maixin-Bio Co., Fujian,
China). Tissue sections (4-mm thick) were placed onto treated slides (Vectabond, Vector
Laboratories, Burlingame, CA, USA). Sections were heat-fixed, deparaffinized, and
rehydrated through a graded alcohol series (100, 95, 85, 75%) to distilled water. Tissue
sections were boiled in citrate buffer at high temperature for antigen retrieval, and
treated with 3% hydrogen peroxide to block endogenous peroxidase activity. The slides
were incubated with a protein-blocking agent (kit 9710 MAIXIN, Maixin-Bio Co.,
Fuzhou, Fujian) prior to the application of the primary antibody, and then incubated
with the primary antibody at 4 °C overnight. The tissues were then incubated with the
secondary biotinylated antispecies antibody and labeled using a modified staining
procedure based on avidin-biotin complex immunoperoxidase following the
instructions provided by the manufacturer of the Ultra-Sensitive SP kit.
For immunofluorescence of tumor tissue, Tissue sections were processed to
incubation with primary antibodies overnight at 4 °C as the same as the instruction of
immunohistochemistry. Then the slides were washed exposed to FITC-conjugated and
PE-conjugated secondary antibodies (1:1000, Invitrogen, CA, USA). A laser scanning
confocal microscope FV10-ASW [Ver 2.1] (Olympus Corp, MPE FV1000) was used
for co-localization analysis.
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5.3 Results & Discussion
5.3.1 GL-V9 had potent anticancer activity in breast cancer cells via
mitochondrial-mediated apoptosis
As shown in Figure 5.6, GL-V9 was a novel synthetic flavonoid derived from the
natural product wogonin that inhibited the growth and induced apoptosis of various
turner cells [115-117]. In previous studies, we have demonstrated that GL-V9 could
inhibit the invasion of human breast carcinoma cells [111]. However, the inhibitory
effect of GL-V9 on the growth of breast cancer has not been reported. As shown in
Figure 5.7, compared with wogonin, GL-V9 has stronger capcity to inhibit the growth
of human breast cancer cells. IC50 values of 36 h GL-V9 treatment were 14.90 ± 1.26
μM and 17.81±2.08 μM for MDA-MB-231 and MCF-7 cells, respectively. And for
wogonin, the IC50 values were 109.22 ± 4.08 μM in MDA-MB-231 cells and 98.53 ±
2.23 μM in MCF-7 cells.

Figure 5.6 Chemical structure of GL-V9 and Wogonin. i) GL-V9 (5-hydroxy-8-methoxy-7-(4(pyrrolidin-1-yl)butoxy)-4H-chromen-4-one, C24H27NO5). ii) wogonin (5,7-Dihydroxy-8methoxy-2-phenyl-4H-chromen-4-one, C16H12O5).
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Figure 5.7 Cell growth inhibition as assayed by MTT. Bars represent SD (±).

To investigate the effect of GL-V9 on inducing apoptosis, fluorescent microscope
was employed. It is observed that untreated MDA-MB-231 and MCF-7 cells stained
equably with blue fluorescence, demonstrating steady chromatinic distribution in
nucleolus. After treatment with 10 μM GL-V9, cells showed an early symptom of
apoptosis and emitted bright fluorescence due to chromatin agglutination and nucleolus
pyknosis. At concentrations of 20 and 30 μM GL-V9, cellular nucleus disintegrated and
formed many nuclear fragments in both cells (Figure 5.8). Upon 30 μM wogonin, only
MCF-7 cells showed nuclear fragments, instead MDA-MB-231 not. As shown in Figure
5.9, the extent of GL-V9 induced apoptosis in MDA-MB-231 and MCF-7 cells is
directly correlated to the concentration of the compound used. Compared to wogonin,
GL-V9 is more than 3 time more efficient in promoting apoptosis in MDA-MB-231
and MCF-7 cells.
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Figure 5.8 Nucleolus morphologic changes induced by wogonin observed under fluorescent
microscope (400×).

Figure 5.9 Annexin-V/PI double-staining assay. Histograms of apoptosis rates were
quantitated using both early and late apoptotic rates. Bars represent SD, *p<0.05 or **p<0.01
versus non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus non-treated
control of MCF-7 cells.

To further study the mechanisms of GL-V9 induced apoptosis, we measured the
expression of key apoptosis proteins in MDA-MB-231 and MCF-7 cells. As shown in
Figure 5.10, upon treatment with GL-V9, caspase 3 was proteolytically activated, and
the expression of caspase 9, Bcl-2 and Bcl-xl was notably decreased, while Bax was
increased. And GL-V9 induced the loss of mitochondrial membrane potential (MMP)
in the two breast cancer cell lines (Figure 5.11). Moreover, the amount of Cyt c
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decreased in mitochondria but increased in the cytosol following GL-V9 treatment
(Figure 5.12), and ROS level was increased as well (Figure 5.13). Little effects on these
mitochondrial apoptosis indexes were observed in the two cancer cell lines when treated
with comparable concentrations (30 μM) of the parent compound wogonin. These
results suggested that GL-V9, more effective than wogonin, inhibited growth and
induced mitochondrial-mediated apoptosis in human breast cancer cells.

Figure 5.10 Western blot assays for the expressions of apoptosis-associated proteins. The
changes of protein expressions were quantified. Bars represent SD, *p<0.05 or **p<0.01 versus
non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus non-treated control of
MCF-7 cells.
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Figure 5.11 JC-1 assay was analyzed by flow cytometry. The percentages of the loss of MMP
were represented by histograms. Bars represent SD, *p<0.05 or **p<0.01 versus non-treated
control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.

Figure 5.12 Western blot assays were used to examine the expressions of cyt-c in mitochondrial
and cytosolic fractions. The changes of protein expressions were quantified. Bars represent
SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01
versus non-treated control of MCF-7 cells.
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Figure 5.13 The level of ROS detected by flow cytometry (Ex/Em = 488 nm/525 nm). Bars
represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05
or ##p<0.01 versus non-treated control of MCF-7 cells.

5.3.2 GL-V9 suppressed glycolysis of human breast cancer cells
Since GL-V9 induced mitochondrial dysfunction in breast cancer cells, it may
influence other mitochondrial functions, especially energy metabolism. Energy
exhaustion was a significant reason for the inhibition of rapidly growing cancer cells.
Cancer cells show an increased dependence on glycolysis to meet their energy needs,
regardless of whether they were well-oxygenated or not. Here, we investigate the
influence of GL-V9 on the aerobic glycolysis in human breast cancer cell lines MDAMB-231 and MCF-7. To exclude the influence of apoptotic death in metabolic
evaluation, we performed a kinetic analysis of cell death and cell growth inhibition from
12 h to 36 h. As shown in Figure 5.14, no obvious cell death of MDA-MB-231 and
MCF-7 cells happened within 24 h treatment of GL-V9. After 24h treatment, cell
survial ratios were rapidly decreased, especially upon 30 μM GL-V9. We further
assayed the apoptosis rates induced by 24 h treatment of GL-V9. The result showed
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that the apoptosis rates were all less than 10% upon 10 μM, 20 μM and 30 μM GL-V9
in both cell lines (Figure 5.15). Thus, we conducted metabolic evaluation upon 24 h
GL-V9 treatment, which inhibited cell growth, but did not induce apoptotic cell death.

Figure 5.14 Growth inhibition of MDA-MB-231 and MCF-7 cells treated by GL-V9 druing 036 h were assayed by MTT. Bars represent SD (±).

Figure 5.15 Annexin-V/PI double-staining assay of MDA-MB-231 and MCF-7 cells treated by
GL-V9 for 24 h.

After treatment with GL-V9 for 24 h, the lactate generation, glucose uptake and ATP
production of MDA-MB-231 and MCF-7 cells were all decreased (Figure 5.16, 5.17
and 5.18). The degree of reduction in these glycolysis indexes depends strongly on the
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concentration of GL-V9. Finally, it is noticed that treatment with GL-V9 significantly
promoted the oxygen consumption of human breast cancer cells between 12 h to 36 h
(Figure 5.19). These results indicated that GL-V9 suppressed glycolysis of breast
cancer cells.

Figure 5.16 Production of lactic acid as assayed with a Lactic Acid production Detection kit.
Bars represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells,
#
p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.

Figure 5.17 Glucose uptake measured using the Amplex Red assay. Bars represent SD, *p<0.05
or **p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus nontreated control of MCF-7 cells.
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Figure 5.18 Quantification of ATP generation detected by the luminometer Orion II. Bars
represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05
or ##p<0.01 versus non-treated control of MCF-7 cells.

Figure 5.19 Oxygen consumption detected by BD Oxygen Biosensor System plate. Bars
represent SD.

5.3.3 The dissociation of HK II from mitochondria accounts for GL-V9 induced
mitochondrial dysfunction and apoptosis
The data above demonstrated that GL-V9 could induce mitochondrial-mediated
apoptosis and inhibit glycolysis. Whether there were some relationships between the
apoptosis-inducing effect and glycolysis modulation? It has been reported that HK II
plays a significant role in both glycolysis and mitochondrial homeostasis [104].
Therefore, we investigated the influence of GL-V9 on mitochondrial HKII in human
breast cancer cell lines MDA-MB-231 and MCF-7. 2-deoxy-D-glucose (2-DG), a
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proven inhibitor that preferentially interfere with the glycolytic pathway in human
breast cancer cells by modulating mitochondria HKII [118], was used as a positive
control. 15 mM 2-DG for 36 h could induced obvious apoptosis in MDA-MB-231 and
MCF-7 cells (Figure 5.20). As shown in Figure 5.21, the level of total and mitochondrial
HKII were both decreased notably with 20 and 30 μM GL-V9 treatment for 36 h. Little
changes on HKII and VDAC were observed for cells treated with 10 μM GL-V9.
Whereas, 15 mM 2-DG only decreased mitochondrial HKII.

i)

ii)

Figure 5.20 Apoptosis induced by 2-DG in human breast cancer cell. 15 mM 2-DG for 36 h
could induced obvious apoptosis in MDA-MB-231 and MCF-7 cells. i) Nucleolus morphologic
changes induced by 2-DG. ii) Annexin-V/PI double-staining assay of MDA-MB-231 and MCF7 cells treated by 2-DG.
i)

ii)
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Figure 5.21 Changes in HK expression in GL-V9 treated human breast cancer cells. i) The
total amount of HKII and VDAC. ii)Mitochondrial and cytosolic fractions of HK II after
treatment. The changes of protein levels were quantified. Bars represent SD, *p<0.05 or
**
p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus nontreated control of MCF-7 cells.

Moreover, the co-localization of HKII with VDAC in human breast cancer cells was
detected by immunofluorescence assay (Figure 5.22). In untreated cells, intense
staining of HKII was detected and co-localized with mitochondrial marker TOMM20.
After GL-V9 and 2-DG treatment, faint diffuse staining of HKII was detected in the
cytosol, indicative of weaker co-localization of HKII with mitochondria. The
subcellular localization of HKII was interdependent, to a large extent, on the interaction
strength of HKII/VDAC[119]. Therefore, to further verify whether the decrease of
mitochondrial HKII was caused by an influence of total protein level or a decrease in
its binding ability with VDAC in mitochondria, we detected the binding of
mitochondrial HKII and VDAC by immunoprecipitation assay. It is found that GL-V9
effectively suppressed the binding of HKII with VDAC in mitochondrial (Figure 5.23).
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Figure 5.22 The co-localization of HKII with VDAC in human breast cancer cells detected by
immunofluorescence assay.
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Figure 5.23 The binding of mitochondrial HKII and VDAC detected by immunoprecipitation
assay. Western blot assays were performed for HK II and VDAC. The changes of protein levels
were quantified. Bars represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDAMB-231 cells, #p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.

5.3.4 The phosphorylation of VDAC by GSK-3β was involved in GL-V9-induced
dissociation of HKII from mitochondria
The interaction of hexokinase with mitochondria is regulated to facilitate apoptotic
effects [14]. We used LiCl (a GSK-3β inhibitor which can induce the
autophosphorylation of GSK-3β) to investigate the roles of GSK-3β in the binding of
HKII to mitochondria. As shown in Figure 5.24, LiCl inhibited the interaction between
HKII and VDAC in both MDA-MB-231 and MCF-7 cells. Although both total and
mitochondrial GSK-3β levels were increased with GL-V9 treatment, phosphorylated
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GSK-3β (GSK-3β(S9)) was actually decreased (Figure 5.25). These results implicated
that GSK-3β was involved in GL-V9-induced dissociation of HK II from VDAC.

Figure 5.24 The influence of LiCl in interaction between HKII and VDAC. Mitochondria were
isolated after LiCl treatment and HK II was immunoprecipitated using VDAC antibody.
Western blot assays were performed for HK II and VDAC. The changes of protein levels were
quantified. Bars represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB231 cells, #p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.

Figure 5.25 The influences of GL-V9 in the expressions of GSK-3β and phosphorylated GSK3β (GSK-3β(s9)). The expressions of GSK-3β and p-GSK-3β in total proteins and
mitochondrial were assayed by Western blot. The changes of protein levels were quantified.
Bars represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells,
#
p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.

This implication is corroborated by our immunoprecipitation experiment that
confirms the binding of GSK-3β with VDAC in mitochondria instead of HKII (Figure
5.26). As shown in Figure 5.27, GL-V9 promoted the binding of mitochondrial GSK3β with VDAC, and phosphorylation of GSK-3β induced by LiCl reversed the effects
of GL-V9. All these results suggested that GL-V9 promoted the binding of GSK-3β
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with VDAC in mitochondria, facilitating the phosphorylation of VDAC and
consequently, the dissociation of HK II from VDCA.

Figure 5.26 The binding of GSK-3β with VDAC and HKII in mitochondria. Mitochondria
were isolated and HK II as well as VDAC was immunoprecipitated using GSK-3β antibody.
Western blot assays were performed for HK II, VDAC and GSK-3β. The changes of protein
levels were quantified. Bars represent SD, *p<0.05 or **p<0.01 versus non-treated control of
MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.

Figure 5.27 The influence of LiCl in the binding of mitochondrial GSK-3β with VDAC that
was promoted by GL-V9. Mitochondria were isolated after GL-V9 with/without LiCl
treatment and VDAC was immunoprecipitated using GSK-3β antibody. Western blot assays
were performed for VDAC and GSK3β. The changes of protein levels were quantified. Bars
represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05
or ##p<0.01 versus non-treated control of MCF-7 cells.

5.3.5 GL-V9 activated GSK-3β in mitochondria via inhibition of AKT
It has been reported that AKT inhibits the activity of GSK-3β in human
neuroblastoma cells by changing its phosphorylation state (phosphorylating Ser9) [120].
Therefore, we investigated the influence of AKT on GSK-3β in human breast cancer
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cells. As shown in Figure 5.28, in human breast cancer cells, insulin-like growth factor
1 (IGF1, an AKT activator) promoted the phosphorylation of GSK-3β,whereas MK2206 (MK, an AKT inhibitor) inhibited the phosphorylation of GSK-3β, in good
agreement with literature report [121]. We further noted that IGF blocked the binding
of GSK-3β with VDAC in mitochondria (Figure 5.29).

Figure 5.28 The influences of IGF-1 and MK in the activation of AKT and GSK-3β. (A) MDAMB-231 and MCF-7 treated with AKT activator (IGF-1) or inhibitor (MK). Western blot
assays for AKT, p-AKT, GSK-3β and p-GSK-3β. The changes of protein levels were quantified.
Bars represent SD, *p<0.05 or **p<0.01 versus non-treated control of MDA-MB-231 cells,
#
p<0.05 or ##p<0.01 versus non-treated control of MCF-7 cells.
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Figure 5.29 The influence of IGF in the binding of GSK-3β with VDAC in mitochondria.
Mitochondria were isolated after AKT activator treatment and GSK-3β was
immunoprecipitated using VDAC antibody. Western blot assays were performed for GSK-3β
and VDAC. The changes of protein levels were quantified. Bars represent SD, *p<0.05 or
**
p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus nontreated control of MCF-7 cells.

Results shown in Figure 5.30 revealed that GL-V9 not only decreased the expression
of AKT but also suppressed its activation, no matter whether GL-V9 induced apoptosis
(36 h treatment) or not (24 h treatment). In the presence of IGF, GL-V9-enhanced
binding of GSK-3β to VDAC in mitochondria was disturbed (Figure 5.31). These
results indicated that inactivation of AKT played important roles in GL-V9-induced
activation of GSK-3β in and the dissociation of HKII from mitochondria.
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Figure 5.30 The influences of GL-V9 in the expression and activation of AKT. The expressions
of AKT and p-AKT (total proteins) upon GL-V9 treatment assayed by Western blot. The
changes of protein levels were quantified. Bars represent SD, *p<0.05 or **p<0.01 versus nontreated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus non-treated control of MCF7 cells.

Figure 5.31 The influence of IGF in GL-V9-enhanced binding of GSK-3β to VDAC in
mitochondria. Mitochondria were isolated after GL-V9 with/without IGF-1 treatment and
GSK-3β was immunoprecipitated using VDCA antibody. Western blot were performed for
VDAC and GSK-3β. The changes of protein levels were quantified. Bars represent SD, *p<0.05
or **p<0.01 versus non-treated control of MDA-MB-231 cells, #p<0.05 or ##p<0.01 versus nontreated control of MCF-7 cells.

5.3.6 GL-V9 inhibited the growth of tumor via activation of GSK-3β and
inactivation of AKT in vivo
To verify the results from our in vitro studies, we investigated the anticancer effects
of GL-V9 on the growth of tumor xenograft models with human MDA-MB-231 or
MCF-7 cell lines. As shown in Figure 5.32-5.34, GL-V9 significantly inhibited the
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growth of tumor in nude mice inoculated with MDA-MB-231 and MCF-7 cells. It is
observed that both GL-V9 and wogonin were as effective as positive drug Taxol for
tumor inoculated with MDA-MB-231 cells. In mice inoculated with MCF-7 cells, GLV9 has similar inhibitory effect with Taxol, but more effective than wogonin. It is worth
mentioning that GL-V9 treatments had little influence on body weight of the animals
(Figure 5.35).

Figure 5.32 The tumor weight of nude mice inoculated with MDA-MB-231 or MCF-7 cells
were treated with saline control, GL-V9, wogonin and Taxol. Bars represent SD, *p<0.05 or
**
p<0.01 versus non-treated control group inoculated with MDA-MB-231 cells, #p<0.05 or
##
p<0.01 versus non-treated control group inoculated with MCF-7 cells.

Figure 5.33 The relative tumor growth inhibitory rate of nude mice inoculated with MDAMB-231 or MCF-7 cells were treated with saline control, GL-V9, wogonin and Taxol.
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Figure 5.34 The tumor volume of nude mice inoculated with MDA-MB-231 or MCF-7 cells
were treated with saline control, GL-V9, wogonin and Taxol. Bars represent SD.

Figure 5.35 The weight of nude mice inoculated with MDA-MB-231 or MCF-7 cells were
treated with saline control, GL-V9, wogonin and Taxol. Bars represent SD.

Hematoxylin and eosin (HE) staining showed that GL-V9-treated group displayed
stronger infiltration and fewer vessels than the control group (Figure 5.36, Table 5.1
and 5.2). Immunohistochemistry (IHC) assay showed that GL-V9 inhibited the
phosphorylation of GSK-3β and the activation of AKT (Figure 5.37), corroborating
with our in vitro studies described in the previous paragraph.
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Figure 5.36 Histological analysis were photographed (×100).
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Table 5.1 Pathology microscopic examination table for the xenograft tissue of MDA-MB-231
cells.

Stroma
Treated Groups

Necrosis
Vessel

Hemorrhage

Infiltration

Score

1

3.5

control

1

1

0.5

GL-V9

0.5

0.5

0.5

1.5

Taxol

1

0.5

0.5

2

Wognin

1

1

1

3

The tumor tissue were assessed by histological analysis. The tags in the table represent the severity :
Minor "±", Mild "1+", Annual "2+", Severe "3+", Extremely severe "4+", and Normal "-" . (H)
Histological analysis were photographed (×100).

Table 5.2 Pathology microscopic examination table for the xenograft tissue of MCF-7 cells.

Stroma
Treated
Necrosis
Groups

Hemorrhag

Infiltration

Score

1

3.5

0.5

2

Vessel
e

control

1

1

0.5

GL-V9

1

0.5

Taxol

1

1

2

Wognin

2

0.5

2.5

The tumor tissue were assessed by histological analysis. The tags in the table represent the severity :
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Minor "±", Mild "1+", Annual "2+", Severe "3+", Extremely severe "4+", and Normal "-" . (H)
Histological analysis were photographed (×100).
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Figure 5.37 Proteins
immunohistochemistry.

expressions

in

breast

tumor

tissue

were

assessed

by

5.4 Conclusion
In this work, we investigated the mechanisms of a newly synthesized flavonoid
named GL-V9 in the inhibition of glycolysis and the induction of apoptosis of human
breast cancer cell lines MDA-MB-231 and MCF-7 cells. We find that hexokinase II
(HKII) plays important roles in the anticancer effects of GL-V9. GL-V9 not only
downregulate the expression of HKII in MDA-MB-231 and MCF-7 cells, but also
induce dissociation of HKII from voltage-dependent anion channel (VDAC) in
mitochondria, resulting in glycolytic inhibition and mitochondrial-mediated apoptosis.
The dissociation of HKII from mitochondria is attributed to GSK-3β-induced
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phosphorylation of mitochondrial VDAC. Moreover, activation of GSK-3β by GL-V9
was resulted from the direct effect of GL-V9 as well as the inactivation of AKT. Our in
vivo experiments also show that GL-V9 significantly inhibits the growth of human
breast cancer due to activation of GSK-3β and inactivation of AKT. Thus, GL-V9
induces cytotoxicity via regulation of HKII binding to mitochondria. Our work
demonstrates the significance of metabolic regulator in cancer growth and offers fresh
insight into the molecular basis for the development of flavonoid as novel agents for
the treatment of breast carcinoma.

Figure 5.38 Schematic diagram of GL-V9-induced inhibition aerobic glycolysis and apoptosis
in human breast cancer cells through GSKβ-mediated disruption of the binding of HKII to
mitochondria. The inhibition of Akt causes the activation of GSK3β which could
phosphorylate VDAC. VDAC phosphorylated by GSK3β is unable to bind HK II in OMM,
thus causing the structural change of mitochondria permeability transition pore, which was
composed by VDAC, Cyp-D and ANT. These changes increased outer mitochondrial
membrane permeability and resulted in the metabolism switch from glycolysis to OXPHOS.
The anticancer effects of GL-V9 is potentiated by detachment of HK II from VDAC, mediated
either by inhibition of AKT and the subsequent activation of GSK3β. Cyp-D, cyclophilin D;
ANT, adenine nucleotide translocator; IMM, inner mitochondrial membrane; OMM, outer
mitochondrial membrane.
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In summary, the present study demonstrated that GL-V9 induced apoptosis and
inhibited aerobic glycolysis by blocking the binding of mitochondrial HKII with VDAC
in human breast cancer cells. The inactivation of AKT and the phosphorylation of
VDAC by GSK-3β were responsible for the disassociation of HKII from mitochondria.
This work provide mechanistic evidence that GL-V9 is a novel candidate for breast
cancer treatment and a potential adjunctive agent for tumor chemotherapy.
The interaction between HKII and mitochondria plays a more important role in
regulating apoptotic responsiveness of cells than merely catalyzing metabolic reactions.
Notably, investigations have showed that upregulated HK2 expression are associated
with drug resistance phenotypes in breast cancer cells [122]. Therefore, HKII may be a
genetic modifier of drug resistance that can be therapeutically exploited. And a better
understanding of the functional differences of HKII in cancer tissue and normal tissues
will undoubtedly contribute to better cancer therapies.

127

REFERENCES
1.

Aoun, S., Chebli, C., and Baloulene, M., Noncovalent immobilization of
chloroperoxidase onto talc: Catalytic properties of a new biocatalyst. Enzyme
And Microbial Technology, 1998. 23(6): p. 380-385.

2.

Aburto, J., Ayala, M., Bustos-Jaimes, I., et al., Stability and catalytic properties
of chloroperoxidase immobilized on SBA-16 mesoporous materials.
Microporous And Mesoporous Materials, 2005. 83(1-3): p. 193-200.

3.

Lakner, F.J. and Hager, L.P., Chloroperoxidase as enantioselective epoxidation
catalyst: An efficient synthesis of (R)-(-)-mevalonolactone. Journal Of Organic
Chemistry, 1996. 61(11): p. 3923-3925.

4.

Bertini, I., Luchinat, C., and Parigi, G., Magnetic susceptibility in paramagnetic
NMR. Progress In Nuclear Magnetic Resonance Spectroscopy, 2002. 40(3): p.
249-273.

5.

Bertini, I., Luchinat, C., Parigi, G., et al., NMR spectroscopy of paramagnetic
metalloproteins. Chembiochem, 2005. 6(9): p. 1536-1549.

6.

deRopp, J.S., Mandal, P., Brauer, S.L., et al., Solution NMR study of the
electronic and molecular structure of the heme cavity in high-spin, resting state
horseradish peroxidase. Journal Of the American Chemical Society, 1997.
119(20): p. 4732-4739.

7.

Allain, E.J., Hager, L.P., Deng, L., et al., Highly Enantioselective Epoxidation
Of Disubstituted Alkenes with Hydrogen-Peroxide Catalyzed by
Chloroperoxidase. Journal Of the American Chemical Society, 1993. 115(10):
p. 4415-4416.

8.

Omura, T., Structural diversity of cytochrome P450 enzyme system. Journal Of
Biochemistry, 2010. 147(3): p. 297-306.

9.

Morris, D.R. and Hager, L.P., Chloroperoxidase. I. Isolation and properties of
the crystalline glycoprotein. J Biol Chem, 1966. 241(8): p. 1763-1768.

10.

Zaks, A. and Dodds, D.R., Chloroperoxidase-Catalyzed Asymmetric Oxidations
- Substrate-Specificity And Mechanistic Study. Journal Of the American
Chemical Society, 1995. 117(42): p. 10419-10424.

11.

Pesic, M., Lopez, C., Alvaro, G., et al., A novel immobilized chloroperoxidase
biocatalyst with improved stability for the oxidation of amino alcohols to amino
aldehydes. Journal Of Molecular Catalysis B-Enzymatic, 2012. 84: p. 144-151.
128

12.

Zaks, A., Yabannavar, A.V., Dodds, D.R., et al., A novel application of
chloroperoxidase: Preparation of gem-halonitro compounds. Journal Of
Organic Chemistry, 1996. 61(24): p. 8692-8695.

13.

Fu, Y.C., Callaway, Z., Lum, J., et al., Exploiting Enzyme Catalysis in UltraLow Ion Strength Media for Impedance Biosensing of Avian Influenza Virus
Using a Bare Interdigitated Electrode. Analytical Chemistry, 2014. 86(4): p.
1965-1971.

14.

Smith, A.T., Pazicni, S., Marvin, K.A., et al., Functional Divergence of HemeThiolate Proteins: A Classification Based on Spectroscopic Attributes.
Chemical Reviews, 2015. 115(7): p. 2532-2558.

15.

Li, X.L., Zhang, J., Jiang, Y.C., et al., Highly Efficient
Biodecolorization/Degradation of Congo Red and Alizarin Yellow R by
Chloroperoxidase from Caldariomyces fumago: Catalytic Mechanism and
Degradation Pathway. Industrial & Engineering Chemistry Research, 2013.
52(38): p. 13572-13579.

16.

Hernandez, K., Berenguer-Murcia, A., Rodrigues, R.C., et al., Hydrogen
Peroxide in Biocatalysis. A Dangerous Liaison. Current Organic Chemistry,
2012. 16(22): p. 2652-2672.

17.

Sheldon, R.A. and van Pelt, S., Enzyme immobilisation in biocatalysis: why,
what and how. Chemical Society Reviews, 2013. 42(15): p. 6223-6235.

18.

Barbosa, O., Ortiz, C., Berenguer-Murcia, A., et al., Strategies for the one-step
immobilization-purification of enzymes as industrial biocatalysts.
Biotechnology Advances, 2015. 33(5): p. 435-456.

19.

Garcia-Galan, C., Berenguer-Murcia, A., Fernandez-Lafuente, R., et al.,
Potential of Different Enzyme Immobilization Strategies to Improve Enzyme
Performance. Advanced Synthesis & Catalysis, 2011. 353(16): p. 2885-2904.

20.

Liese, A. and Hilterhaus, L., Evaluation of immobilized enzymes for industrial
applications. Chemical Society Reviews, 2013. 42(15): p. 6236-6249.

21.

Peirce, S., Virgen-Ortiz, J.J., Tacias-Pascacio, V.G., et al., Development of
simple protocols to solve the problems of enzyme coimmobilization. Application
to coimmobilize a lipase and a beta-galactosidase. Rsc Advances, 2016. 6(66):
p. 61707-61715.

129

22.

Singh, R.K., Tiwari, M.K., Singh, R., et al., Immobilization of L-arabinitol
dehydrogenase on aldehyde-functionalized silicon oxide nanoparticles for Lxylulose production. Applied Microbiology And Biotechnology, 2014. 98(3): p.
1095-1104.

23.

Sundaramoorthy, M., Terner, J., and Poulos, T.L., Stereochemistry of the
chloroperoxidase active site: crystallographic and molecular-modeling studies.
Chemistry & Biology, 1998. 5(9): p. 461-473.

24.

Aitken, M.D., Massey, I.J., Chen, T.P., et al., Characterization Of ReactionProducts From the Enzyme-Catalyzed Oxidation Of Phenolic Pollutants. Water
Research, 1994. 28(9): p. 1879-1889.

25.

Littlechild, J., Haloperoxidases and their role in biotransformation reactions.
Current Opinion In Chemical Biology, 1999. 3(1): p. 28-34.

26.

Karam, J. and Nicell, J.A., Potential applications of enzymes in waste treatment.
Journal Of Chemical Technology And Biotechnology, 1997. 69(2): p. 141-153.

27.

Scarsi, K.K., Olaitan, O.O., Rawizza, H.E., et al., Building capacity through
implementation of a clinical pharmacy training model for HIV medicine.
Pharmacotherapy, 2015. 35(11): p. E241-E241.

28.

Pandey, A., Lee, D.J., Mohan, S.V., et al., Preface-1st International Conference
on Bioresource Technology for Bioenergy, Bioproducts & Environmental
Sustainability (BIORESTEC). Renewable Energy, 2018. 129: p. 677-677.

29.

Hager, L.P., Lakner, F.J., and Basavapathruni, A., Chiral synthons via
chloroperoxidase catalysis. Journal Of Molecular Catalysis B-Enzymatic, 1998.
5(1-4): p. 95-101.

30.

Huynh, D.L., Sharma, N., Singh, A.K., et al., Anti-tumor activity of wogonin,
an extract from Scutellaria baicalensis, through regulating different signaling
pathways. Chinese Journal Of Natural Medicines, 2017. 15(1): p. 15-40.

31.

Wu, X., Zhang, H.J., Salmani, J.M.M., et al., Advances of wogonin, an extract
from Scutellaria baicalensis, for the treatment of multiple tumors. Oncotargets
And Therapy, 2016. 9: p. 2935-2943.

32.

Zhi, L.F., Jiang, Y.C., Wang, Y.S., et al., Effects of additives on the
thermostability of chloroperoxidase. Biotechnology Progress, 2007. 23(3): p.
729-733.

130

33.

Hager, L.P., Morris, D.R., Brown, F.S., et al., Chloroperoxidase. II. Utilization
of halogen anions. J Biol Chem, 1966. 241(8): p. 1769-1777.

34.

Dai, K., Lu, L.H., Liu, Q., et al., Sonication assisted preparation of graphene
oxide/graphitic-C3N4 nanosheet hybrid with reinforced photocurrent for
photocatalyst applications. Dalton Transactions, 2014. 43(17): p. 6295-6299.

35.

Mandal, P. and Chattopadhyay, A.P., Excellent catalytic activity of magnetically
recoverable Fe3O4-graphene oxide nanocomposites prepared by a simple
method. Dalton Transactions, 2015. 44(25): p. 11444-11456.

36.

Zhang, J., Feng, M.Y., Jiang, Y.C., et al., Efficient decolorization/degradation
of aqueous azo dyes using buffered H2O2 oxidation catalyzed by a dosage
below ppm level of chloroperoxidase. Chemical Engineering Journal, 2012. 191:
p. 236-242.

37.

Jiao, R.J., Tan, Y., Jiang, Y.C., et al., Ordered Mesoporous Silica Matrix for
Immobilization of Chloroperoxidase with Enhanced Biocatalytic Performance
for Oxidative Decolorization of Azo Dye. Industrial & Engineering Chemistry
Research, 2014. 53(31): p. 12201-12208.

38.

Zhang, J.T., Jiang, J.W., and Zhao, X.S., Synthesis and Capacitive Properties of
Manganese Oxide Nanosheets Dispersed on Functionalized Graphene Sheets.
Journal Of Physical Chemistry C, 2011. 115(14): p. 6448-6454.

39.

Li, Q.Z., Fan, F., Wang, Y., et al., Enzyme Immobilization on CarboxylFunctionalized Graphene Oxide for Catalysis in Organic Solvent. Industrial &
Engineering Chemistry Research, 2013. 52(19): p. 6343-6348.

40.

Thy, L.T.M., Thuong, N.H., Tu, T.H., et al., Synthesis of magnetic iron
oxide/graphene oxide nanocomposites for removal of cadmium ions from water.
Advances in Natural Sciences: Nanoscience and Nanotechnology, 2019. 10(2):
p. 025006.

41.

Kassaee, M.Z., Motamedi, E., and Majdi, M., Magnetic Fe3O4-graphene
oxide/polystyrene: Fabrication and characterization of a promising
nanocomposite. Chemical Engineering Journal, 2011. 172(1): p. 540-549.

42.

Jung, D., Streb, C., and Hartmann, M., Oxidation of indole using
chloroperoxidase and glucose oxidase immobilized on SBA-15 as tandem
biocatalyst. Microporous And Mesoporous Materials, 2008. 113(1-3): p. 523529.

131

43.

Holzinger, M., Singh, M., and Cosnier, S., Biotin-beta-Cyclodextrin: A New
Host Guest System for the Immobilization of Biomolecules. Langmuir, 2012.
28(34): p. 12569-12574.

44.

Srejber, M., Navratilova, V., Paloncyova, M., et al., Membrane-attached
mammalian cytochromes P450: An overview of the membrane's effects on
structure, drug binding, and interactions with redox partners. Journal Of
Inorganic Biochemistry, 2018. 183: p. 117-136.

45.

Dai, Y.J., Zhen, J., Zhang, X.L., et al., Analysis of the complex formation,
interaction and electron transfer pathway between the "open" conformation of
NADPH-cytochrome P450 reductase and aromatase. Steroids, 2015. 101: p.
116-124.

46.

Yang, C.Q., Lu, S., Mao, Y.B., et al., Characterization of two NADPH:
Cytochrome P450 reductases from cotton (Gossypium hirsutum).
Phytochemistry, 2010. 71(1): p. 27-35.

47.

Li, X.H., Zhu, H., Feng, J., et al., One-pot polylol synthesis of graphene
decorated with size- and density-tunable Fe3O4 nanoparticles for porcine
pancreatic lipase immobilization. Carbon, 2013. 60: p. 488-497.

48.

De Matteis, L., Germani, R., Mancini, M.V., et al., Encapsulation of
chloroperoxidase in novel hybrid polysaccharide-silica biocomposites:
Catalytic efficiency, re-use and thermal stability. Applied Catalysis a-General,
2015. 492: p. 23-30.

49.

Bayramoglu, G., Kiralp, S., Yilmaz, M., et al., Covalent immobilization of
chloroperoxidase onto magnetic beads: Catalytic properties and stability.
Biochemical Engineering Journal, 2008. 38(2): p. 180-188.

50.

Perez, D.I., van Rantwijk, F., and Sheldon, R.A., Cross-Linked Enzyme
Aggregates of Chloroperoxidase: Synthesis, Optimization and Characterization.
Advanced Synthesis & Catalysis, 2009. 351(13): p. 2133-2139.

51.

Wang, W., Xu, Y., Wang, D.I.C., et al., Recyclable Nanobiocatalyst for
Enantioselective Sulfoxidation: Facile Fabrication and High Performance of
Chloroperoxidase-Coated Magnetic Nanoparticles with Iron Oxide Core and
Polymer Shell. Journal Of the American Chemical Society, 2009. 131(36): p.
12892-+.

132

52.

Wu, L.T., Wu, S.S., Xu, Z., et al., Modified nanoporous titanium dioxide as a
novel carrier for enzyme immobilization. Biosensors & Bioelectronics, 2016.
80: p. 59-66.

53.

Palucki, M., Pospisil, P.J., Zhang, W., et al., Highly Enantioselective, LowTemperature Epoxidation Of Styrene. Journal Of the American Chemical
Society, 1994. 116(20): p. 9333-9334.

54.

Kiljunen, E. and Kanerva, L.T., Chloroperoxidase-catalysed oxidation of
alcohols to aldehydes. Journal Of Molecular Catalysis B-Enzymatic, 2000. 9(46): p. 163-172.

55.

China, H., Okada, Y., and Dohi, T., The Multiple Reactions in the
Monochlorodimedone Assay: Discovery of Unique Dehalolactonizations under
Mild Conditions. Asian Journal Of Organic Chemistry, 2015. 4(10): p. 10651074.

56.

Vold, R.L., Waugh, J.S., Klein, M.P., et al., Measurement of Spin Relaxation in
Complex Systems. The Journal of Chemical Physics, 1968. 48(8): p. 3831-3832.

57.

Rea, V., Kolkman, A.J., Vottero, E., et al., Active Site Substitution A82W
Improves the Regioselectivity of Steroid Hydroxylation by Cytochrome P450
BM3 Mutants As Rationalized by Spin Relaxation Nuclear Magnetic Resonance
Studies. Biochemistry, 2012. 51(3): p. 750-760.

58.

Buyukcelik, A., Yalcin, B., and Utkan, G., Multidisciplinary management of
lung cancer. New England Journal Of Medicine, 2004. 350(19): p. 2009-2009.

59.

Jemal, A., Bray, F., Center, M.M., et al., Global Cancer Statistics. Ca-a Cancer
Journal for Clinicians, 2011. 61(2): p. 69-90.

60.

Gridelli, C., Rossi, A., Carbone, D.P., et al., Non-small-cell lung cancer. Nature
Reviews Disease Primers, 2015. 1.

61.

Ferlay, J., Soerjomataram, I., Dikshit, R., et al., Cancer incidence and mortality
worldwide: Sources, methods and major patterns in GLOBOCAN 2012.
International Journal Of Cancer, 2015. 136(5): p. E359-E386.

62.

Govindan, R., Page, N., Morgensztern, D., et al., Changing epidemiology of
small-cell lung cancer in the United States over the last 30 years: Analysis of
the surveillance, epidemiologic, and end results database. Journal Of Clinical
Oncology, 2006. 24(28): p. 4539-4544.

133

63.

Travis, W.D., Brambilla, E., and Riely, G.J., New Pathologic Classification of
Lung Cancer: Relevance for Clinical Practice and Clinical Trials. Journal Of
Clinical Oncology, 2013. 31(8): p. 992-1001.

64.

Shi, L., Zhang, B., Sun, X., et al., MiR-204 inhibits human NSCLC metastasis
through suppression of NUAK1. British Journal Of Cancer, 2014. 111(12): p.
2316-2327.

65.

Adams, J.M. and Cory, S., The Bcl-2 apoptotic switch in cancer development
and therapy. Oncogene, 2007. 26(9): p. 1324-1337.

66.

Meng, J.R., Fang, B.L., Liao, Y., et al., Apoptosis Induction by MEK Inhibition
in Human Lung Cancer Cells Is Mediated by Bim. Plos One, 2010. 5(9).

67.

Zhang, L.N., Li, J.Y., and Xu, W., A review of the role of Puma, Noxa and Bim
in the tumorigenesis, therapy and drug resistance of chronic lymphocytic
leukemia. Cancer Gene Therapy, 2013. 20(1): p. 1-7.

68.

Nordigarden, A., Kraft, M., Eliasson, P., et al., BH3-only protein Bim more
critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human
leukemic cells and transduced hematopoietic progenitors carrying oncogenic
FLT3. Blood, 2009. 113(10): p. 2302-2311.

69.

Cragg, M.S., Kuroda, J., Puthalakath, H., et al., Gefitinib-induced killing of
NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced
by BH3 mimetics. Plos Medicine, 2007. 4(10): p. 1681-1690.

70.

Croce, C.M. and Reed, J.C., Finally, An Apoptosis-Targeting Therapeutic for
Cancer. Cancer Research, 2016. 76(20): p. 5914-5920.

71.

Calnan, D.R. and Brunet, A., The FoxO code. Oncogene, 2008. 27(16): p. 22762288.

72.

Yang, J.Y., Xia, W., and Hu, M.C.T., Ionizing radiation activates expression of
FOXO3a, Fas ligand, and Bim, and induces cell apoptosis. International Journal
Of Oncology, 2006. 29(3): p. 643-648.

73.

Schmidt, M., de Mattos, S.F., van der Horst, A., et al., Cell cycle inhibition by
FoxO forkhead transcription factors involves downregulation of cyclin D.
Molecular And Cellular Biology, 2002. 22(22): p. 7842-7852.

134

74.

Medema, R.H., Kops, G.J.P.L., Bos, J.L., et al., AFX-like Forkhead
transcription factors mediate cell-cycle regulation by Ras and PKB through
p27(kip1). Nature, 2000. 404(6779): p. 782-787.

75.

Tran, H., Brunet, A., Grenier, J.M., et al., DNA repair pathway stimulated by the
forkhead transcription factor FOXO3a through the Gadd45 protein. Science,
2002. 296(5567): p. 530-534.

76.

Brunet, A., Bonni, A., Zigmond, M.J., et al., Akt promotes cell survival by
phosphorylating and inhibiting a forkhead transcription factor. Cell, 1999.
96(6): p. 857-868.

77.

Qiang, W., Sui, F., Ma, J.J., et al., Proteasome inhibitor MG132 induces thyroid
cancer cell apoptosis by modulating the activity of transcription factor FOXO3a.
Endocrine, 2017. 56(1): p. 98-108.

78.

Fitzwalter, B.E., Towers, C.G., Sullivan, K.D., et al., Autophagy Inhibition
Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a
Turnover. Developmental Cell, 2018. 44(5): p. 555-+.

79.

van der Horst, A. and Burgering, B.M.T., Stressing the role of FoxO proteins in
lifespan and disease. Nature Reviews Molecular Cell Biology, 2007. 8(6): p.
440-450.

80.

Mcguirk, P.R., Jefson, M.R., Mann, D.D., et al., Synthesis And StructureActivity-Relationships
Of
7-Diazabicycloalkylquinolones,
Including
Danofloxacin, a New Quinolone Antibacterial Agent for Veterinary-Medicine.
Journal Of Medicinal Chemistry, 1992. 35(4): p. 611-620.

81.

Knoll, U., Glunder, G., and Kietzmann, M., Comparative study of the plasma
pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin
in broiler chickens. Journal Of Veterinary Pharmacology And Therapeutics,
1999. 22(4): p. 239-246.

82.

Sappal, R., Chaudhary, R.K., Sandhu, H.S., et al., Pharmacokinetics, urinary
excretion and plasma protein binding of danofloxacin following intravenous
administration in buffalo calves (Bubalus bubalis). Veterinary Research
Communications, 2009. 33(7): p. 659-667.

83.

Qiang, L., Yang, Y., You, Q.D., et al., Inhibition of glioblastoma growth and
angiogenesis by garnbogic acid: An in vitro and in vivo study. Biochemical
Pharmacology, 2008. 75(5): p. 1083-1092.

135

84.

Zhang, X.P., Chen, J., Graham, S.H., et al., Intranuclear localization of
apoptosis-inducing factor (AIF) and large scale dna fragmentation after
traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite.
Journal Of Neurochemistry, 2002. 82(1): p. 181-191.

85.

Tao, L., Fu, R., Wang, X.P., et al., LL-202, a newly synthesized flavonoid,
inhibits tumor growth via inducing G(2)/M phase arrest and cell apoptosis in
MCF-7 humanbreast cancer cells in vitro and in vivo. Toxicology Letters, 2014.
228(1): p. 1-12.

86.

Abu-Hamad, S., Zaid, H., Israelson, A., et al., Hexokinase-I protection against
apoptotic cell death is mediated via interaction with the voltage-dependent
anion channel-1 - Mapping the site of binding. Journal Of Biological Chemistry,
2008. 283(19): p. 13482-13490.

87.

Zhao, Y., Guo, Q.L., Zhao, K., et al., Small molecule GL-V9 protects against
colitis-associated colorectal cancer by limiting NLRP3 inflammasome through
autophagy. Oncoimmunology, 2018. 7(1).

88.

DeSantis, C.E., Ma, J., Sauer, A.G., et al., Breast cancer statistics, 2017, racial
disparity in mortality by state. Ca-a Cancer Journal for Clinicians, 2017. 67(6):
p. 439-448.

89.

Zheng, R.S., Zeng, H.M., Zhang, S.W., et al., Estimates of cancer incidence and
mortality in China, 2013. Chinese Journal Of Cancer, 2017. 36.

90.

Picon-Ruiz, M., Morata-Tarifa, C., Valle-Goffin, J.J., et al., Obesity and Adverse
Breast Cancer Risk and Outcome: Mechanistic Insights and Strategies for
Intervention. Ca-a Cancer Journal for Clinicians, 2017. 67(5): p. 379-397.

91.

Pierobon, M. and Frankenfeld, C.L., Obesity as a risk factor for triple-negative
breast cancers: a systematic review and meta-analysis. Breast Cancer Research
And Treatment, 2013. 137(1): p. 307-314.

92.

Bray, F., Ferlay, J., Soerjomataram, I., et al., Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
185 countries. Ca-a Cancer Journal for Clinicians, 2018. 68(6): p. 394-424.

93.

Warburg, O., On the origin of cancer cells. Science, 1956. 123(3191): p. 309314.

94.

Hanahan, D. and Weinberg, R.A., Hallmarks of cancer: the next generation.
Cell, 2011. 144(5): p. 646-674.
136

95.

Zhivotovsky, B. and Orrenius, S., The Warburg Effect returns to the cancer
stage. Semin Cancer Biol, 2009. 19(1): p. 1-3.

96.

Mathupala, S.P., Ko, Y.H., and Pedersen, P.L., Hexokinase II: Cancer's doubleedged sword acting as both facilitator and gatekeeper of malignancy when
bound to mitochondria. Oncogene, 2006. 25(34): p. 4777-4786.

97.

Hamanaka, R.B. and Chandel, N.S., Warburg Effect and Redox Balance.
Science, 2011. 334(6060): p. 1219-1220.

98.

Rosano, C., Molecular model of hexokinase binding to the outer mitochondrial
membrane porin (VDAC1): Implication for the design of new cancer therapies.
Mitochondrion, 2011. 11(3): p. 513-519.

99.

Heiden, M.G.V., Cantley, L.C., and Thompson, C.B., Understanding the
Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science,
2009. 324(5930): p. 1029-1033.

100.

Bustamante, E. and Pedersen, P.L., High aerobic glycolysis of rat hepatoma
cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A,
1977. 74(9): p. 3735-3739.

101.

Pastorino, J.G. and Hoek, J.B., Regulation of hexokinase binding to VDAC. J
Bioenerg Biomembr, 2008. 40(3): p. 171-182.

102.

Hashimoto, M. and Wilson, J.E., Membrane potential-dependent
conformational changes in mitochondrially bound hexokinase of brain.
Archives Of Biochemistry And Biophysics, 2000. 384(1): p. 163-173.

103.

Patra, K.C., Wang, Q., Bhaskar, P.T., et al., Hexokinase 2 Is Required for Tumor
Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse
Models of Cancer. Cancer Cell, 2013. 24(2): p. 213-228.

104.

Shulga, N., Wilson-Smith, R., and Pastorino, J.G., Sirtuin-3 deacetylation of
cyclophilin D induces dissociation of hexokinase II from the mitochondria.
Journal Of Cell Science, 2010. 123(6): p. 894-902.

105.

Pastorino, J.G. and Hoek, J.B., Hexokinase II: The integration of energy
metabolism and control of apoptosis. Current Medicinal Chemistry, 2003.
10(16): p. 1535-1551.

106.

Vara, J.A.F., Casado, E., de Castro, J., et al., PI3K/Akt signalling pathway and
cancer. Cancer Treatment Reviews, 2004. 30(2): p. 193-204.
137

107.

Miyamoto, S., Murphy, A.N., and Brown, J.H., Akt mediates mitochondrial
protection in cardiomyocytes through phosphorylation of mitochondrial
hexokinase-II. Faseb Journal, 2008. 22.

108.

Watcharasit, P., Bijur, G.N., Song, L., et al., Glycogen synthase kinase-3 beta
(GSK3 beta) binds to and promotes the actions of p53. Journal Of Biological
Chemistry, 2003. 278(49): p. 48872-48879.

109.

Robey, R.B. and Hay, N., Mitochondrial hexokinases, novel mediators of the
antiapoptotic effects of growth factors and Akt. Oncogene, 2006. 25(34): p.
4683-4696.

110.

Pastorino, J.G. and Hoek, J.B., Regulation of hexokinase binding to VDAC.
Journal Of Bioenergetics And Biomembranes, 2008. 40(3): p. 171-182.

111.

Li, L.W., Chen, P., Ling, Y., et al., Inhibitory effects of GL-V9 on the invasion
of human breast carcinoma cells by downregulating the expression and activity
of matrix metalloproteinase-2/9. European Journal Of Pharmaceutical Sciences,
2011. 43(5): p. 393-399.

112.

Li, L.W., Lu, N., Dai, Q.S., et al., GL-V9, a newly synthetic flavonoid derivative,
induces mitochondrial-mediated apoptosis and G2/M cell cycle arrest in human
hepatocellular carcinoma HepG2 cells. European Journal Of Pharmacology,
2011. 670(1): p. 13-21.

113.

Zhao, L., Li, W., Zhou, Y.X., et al., The overexpression and nuclear
translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP,
and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis. Free
Radical Biology And Medicine, 2015. 82: p. 29-41.

114.

Wei, L., Lu, N., Dai, Q., et al., Different apoptotic effects of wogonin via
induction of H(2)O(2) generation and Ca(2+) overload in malignant hepatoma
and normal hepatic cells. J Cell Biochem, 2010. 111(6): p. 1629-1641.

115.

Wei, L.B., Lu, N., Dai, Q.S., et al., Different Apoptotic Effects of Wogonin Via
Induction of H2O2 Generation and Ca2+ Overload in Malignant Hepatoma
and Normal Hepatic Cells. Journal Of Cellular Biochemistry, 2010. 111(6): p.
1629-1641.

116.

He, L.C., Lu, N., Dai, Q.S., et al., Wogonin induced G1 cell cycle arrest by
regulating Wnt/beta-catenin signaling pathway and inactivating CDK8 in
human colorectal cancer carcinoma cells. Toxicology, 2013. 312: p. 36-47.

138

117.

Xu, X.F., Zhang, Y., Li, W., et al., Wogonin reverses multi-drug resistance of
human myelogenous leukemia K562/A02 cells via downregulation of MRP1
expression by inhibiting Nrf2/ARE signaling pathway. Biochemical
Pharmacology, 2014. 92(2): p. 220-234.

118.

Ganapathy-Kanniappan, S. and Geschwind, J.F.H., Tumor glycolysis as a target
for cancer therapy: progress and prospects. Molecular Cancer, 2013. 12.

119.

Chiara, F., Castellaro, D., Marin, O., et al., Hexokinase II Detachment from
Mitochondria Triggers Apoptosis through the Permeability Transition Pore
Independent of Voltage-Dependent Anion Channels. Plos One, 2008. 3(3).

120.

Lee, J.E., Kang, J.S., Ki, Y.W., et al., Akt/GSK3 beta signaling is involved in
fipronil-induced apoptotic cell death of human neuroblastoma SH-SY5Y cells.
Toxicology Letters, 2011. 202(2): p. 133-141.

121.

Ma, X.M. and Bai, Y.R., IGF-1 activates the P13K/AKT signaling pathway via
upregulation of secretory clusterin. Molecular Medicine Reports, 2012. 6(6): p.
1433-1437.

122.

Komurov, K., Tseng, J.T., Muller, M., et al., The glucose-deprivation network
counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer
cells. Molecular Systems Biology, 2012. 8.

139

APPENDIX
Figure A1. DNA sequence of full-length WT CPO gene.
ATGTTCTCCAAGGTCCTTCCCTTCGTGGGAGCGGTTGCCGCCCTCCCTCAC
TCCGTCCGTCAGGAGCCTGGCTCCGGCATTGGCTACCCATACGACAACAAC
ACCCTGCCATATGTCGCCCCAGGTCCTACCGACTCTCGTGCTCCTTGCCCAG
CTCTGAACGCTCTTGCCAACCACGGTTACATTCCTCACGATGGCCGTGCCA
TCAGCAGGGAGACCCTCCAGAACGCTTTCCTCAACCACATGGGTATTGCCA
ACTCCGTCATTGAGCTTGCTCTGACCAACGCCTTCGTCGTCTGCGAGTACG
TTACTGGCTCCGACTGTGGTGACAGCCTTGTCAACCTGACTCTGCTCGCCG
AGCCCCACGCTTTCGAGCACGACCACTCCTTCTCCCGCAAGGATTACAAGC
AGGGTGTCGCCAACTCCAACGACTTCATCGACAACAGGAACTTCGATGCC
GAGACCTTCCAGACCTCTCTGGATGTCGTTGCAGGCAAGACCCACTTCGAC
TATGCCGACATGAACGAGATCCGCCTTCAGCGCGAGTCCCTCTCCAACGAG
CTTGACTTCCCCGGTTGGTTCACCGAGTCCAAGCCAATCCAGAACGTCGAG
TCTGGCTTCATCTTCGCCCTTGTCTCTGACTTCAACCTGCCCGACAACGATG
AGAACCCTCTGGTTCGCATTGACTGGTGGAAGTACTGGTTCACCAACGAGT
CCTTCCCATACCACCTCGGCTGGCACCCCCCGTCTCCAGCCAGGGAGATCG
AGTTCGTCACCTCCGCCTCCTCCGCTGTCCTGGCTGCCTCTGTCACCTCTAC
TCCATCTTCCCTTCCATCCGGTGCCATCGGCCCAGGTGCCGAGGCTGTCCCT
CTCTCCTTCGCCTCCACCATGACCCCATTCCTCCTCGCCACCAATGCTCCTT
ACTACGCCCAGGACCCAACTCTCGGCCCCAACGACAAGCGTGAGGCTGCC
CCAGCTGCCACCACCTCCATGGCCGTCTTCAAGAACCCATACCTCGAGGCC
ATTGGCACCCAGGACATCAAGAACCAGCAGGCTTACGTCAGCTCCAAGGC
TGCTGCCATGGCCTCTGCCATGGCCGCCAACAAGGCCCGCAACCTTTAA
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